{"gene":"HLF","run_date":"2026-04-28T18:06:53","timeline":{"discoveries":[{"year":1992,"finding":"HLF (hepatic leukemia factor) encodes a PAR-subfamily basic leucine zipper (bZIP) transcription factor normally expressed in liver and kidney; the t(17;19) chromosomal translocation fuses the E2A transactivation domain to the HLF bZIP domain, creating the chimeric E2A-HLF oncoprotein in acute B-lineage leukemia.","method":"Molecular cloning, Northern blot, chimeric transcript sequencing","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 — original cloning with direct molecular characterization, replicated by independent lab same year","pmids":["1386162","1516826"],"is_preprint":false},{"year":1992,"finding":"Wild-type HLF binds DNA specifically as a homodimer or heterodimer with other PAR family factors (DBP, TEF); the E2A-HLF fusion protein has markedly impaired homodimerization but retains heterodimeric DNA binding with PAR proteins, suggesting a novel mechanism for leukemogenic conversion.","method":"Gel mobility shift assay, in vitro DNA-binding, dimerization assays","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1 — direct in vitro binding assays with mutagenesis-level structural dissection","pmids":["1516826"],"is_preprint":false},{"year":1994,"finding":"HLF and E2A-HLF selectively bind the consensus DNA sequence 5'-GTTACGTAAT-3' with high affinity; E2A-HLF chimeras show reduced tolerance for sequence deviations due to loss of an HLF ancillary DNA-binding domain, and both activate transcription from consensus-site reporter genes in lymphoid and non-lymphoid cells, but E2A-HLF can competitively inhibit wild-type PAR protein activation at suboptimal binding sites.","method":"In vitro binding site selection, gel shift assay, transient transfection reporter assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 — in vitro binding site selection plus functional reporter assays with multiple cell types","pmids":["8065331"],"is_preprint":false},{"year":1995,"finding":"The rat HLF gene is transcribed from two alternative promoters (alpha and beta) producing a 43 kDa protein (HLF43, abundant in brain/liver/kidney) and a novel 36 kDa protein (HLF36, liver-specific, initiated from a CUG codon); the two isoforms accumulate with different circadian amplitudes and have distinct liver-specific promoter preferences in transfection experiments—HLF43 preferentially activates the cholesterol 7α-hydroxylase promoter while HLF36 preferentially activates the albumin promoter.","method":"Alternative promoter characterization, CUG-initiation identification, Western blot, transfection reporter assays, circadian expression analysis","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal methods (promoter mapping, translation initiation, functional transactivation assays)","pmids":["7556072"],"is_preprint":false},{"year":1995,"finding":"E2A-HLF-mediated cell transformation requires both the bipartite E2A transactivation domains and the HLF leucine zipper dimerization domain; mutants lacking either the E2A activation domains or the HLF leucine zipper fail to transform NIH 3T3 cells or support anchorage-independent growth and tumor formation in nude mice.","method":"NIH 3T3 transformation assay, soft agar colony formation, nude mouse tumor xenograft, deletion mutagenesis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — loss-of-function mutagenesis with multiple phenotypic readouts including in vivo tumorigenesis","pmids":["7760820"],"is_preprint":false},{"year":1996,"finding":"The E2A-HLF chimeric oncoprotein reverses apoptosis in murine pro-B lymphocytes, blocking both IL-3 withdrawal-induced and p53-mediated cell death; dominant-negative suppression of E2A-HLF in human t(17;19) leukemia cells rapidly induced apoptosis, demonstrating that the oncoprotein promotes cell survival rather than growth.","method":"Dominant-negative suppressor expression, IL-3 deprivation apoptosis assay, p53-mediated apoptosis assay in pro-B cells","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — clean gain- and loss-of-function experiments with defined apoptotic phenotype, published in Nature","pmids":["8700228"],"is_preprint":false},{"year":1996,"finding":"TEF and HLF share identical DNA-binding consensus sequences (5'-GTTACGTAAT-3') and possess a highly conserved ~40 amino acid transcriptional activation domain (THAD) whose deletion completely abrogates transcriptional activity in both mammalian cells and yeast; this THAD represents one of the most evolutionarily conserved transcriptional activation domains identified.","method":"Binding site selection assay, GAL4 fusion deletion mapping, reporter assays in mammalian cells and yeast","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 — in vitro binding selection plus functional deletion mapping with cross-species validation","pmids":["8639829"],"is_preprint":false},{"year":1997,"finding":"E2A-HLF transforms cells through homodimeric binding to downstream target gene promoters (gain-of-function), not through dominant-negative interference with wild-type PAR proteins; leucine zipper mutants that can homodimerize but cannot heterodimerize with HLF/TEF/DBP retain full transforming activity, and transformation requires intact E2A activator regions.","method":"Leucine zipper domain mutagenesis (extended helix, charged residue alterations), NIH 3T3 soft agar transformation assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 — structure-function mutagenesis distinguishing homodimer vs. heterodimer mechanisms with functional readout","pmids":["9032268"],"is_preprint":false},{"year":1997,"finding":"E2A-PBX1 and E2A-HLF chimeric oncoproteins concentrate within discrete spherical nuclear domains (chimeric-E2A oncoprotein domains, CODs) that require protein elements from both fusion partners; wild-type E2A or PBX1 alone show diffuse nuclear distribution, indicating COD formation is a gain-of-function property of the chimera.","method":"Immunofluorescence microscopy, nuclear localization analysis, co-transfection experiments","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 3 — localization by immunofluorescence, functional link to transcription suggested but not confirmed","pmids":["9366523"],"is_preprint":false},{"year":1998,"finding":"The antiapoptotic activity of E2A-HLF in IL-3-deprived pro-B cells depends critically on the E2A transactivation domains (AD1 and AD2), not on DNA binding or leucine zipper-mediated dimerization through the HLF bZIP domain; bZIP-disabled mutants retaining either E2A activation domain still extend cell survival, suggesting protein-protein interactions via the E2A N-terminus allow the chimera to act as a transcriptional cofactor.","method":"Zinc-inducible expression of E2A-HLF deletion/point mutants in FL5.12 IL-3-dependent pro-B cells, apoptosis assay upon IL-3 withdrawal","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — systematic structure-function analysis with panel of mutants and defined cellular phenotype","pmids":["9742120"],"is_preprint":false},{"year":1998,"finding":"The E2A-HLF chimera abrogates p53-induced apoptosis in myeloid leukemia cells, acting downstream of p53 since p53-responsive genes (p21, Bax) are still normally upregulated; NFIL3, a related bZIP protein binding the same consensus site, cannot substitute for this anti-p53 function, indicating E2A-HLF has unique cell-type-specific survival properties.","method":"Temperature-sensitive p53 mutant M1 myeloid cell system, enforced E2A-HLF expression, apoptosis assay, p53-target gene expression analysis","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — epistasis experiment placing E2A-HLF downstream of p53 with defined molecular readouts","pmids":["9694729"],"is_preprint":false},{"year":1999,"finding":"HLF and E2A-HLF transactivate the HBV enhancer II (EnII) through binding to nucleotides 1640–1663; specifically, HLF activates the core upstream regulatory sequence and predominantly stimulates pregenome RNA synthesis, while FTF activates the full enhancer; E4BP4 binding to the same site has opposing repressive effects.","method":"Yeast one-hybrid screening, transient transfection reporter assays, primer extension analysis","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2–3 — yeast one-hybrid binding plus functional reporter assays; single lab","pmids":["10627534"],"is_preprint":false},{"year":1999,"finding":"E2A-HLF activates expression of SLUG, a zinc-finger transcription factor of the Snail family closely related to C. elegans CES-1 antiapoptotic protein; SLUG expression is nearly as effective as Bcl-2 or Bcl-xL in promoting survival of IL-3-deprived pro-B cells, establishing SLUG as a downstream effector of E2A-HLF in blocking apoptosis.","method":"E2A-HLF-responsive gene search, SLUG identification, IL-3 withdrawal survival assay with Bcl-2/Bcl-xL comparison","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 — gene identification with direct functional validation of downstream effector via survival assay","pmids":["10518215"],"is_preprint":false},{"year":1999,"finding":"E2A-HLF transgenic mice (lymphoid-directed expression) exhibit T-cell apoptosis, B-cell maturation arrest at an early developmental stage, and susceptibility to infection due to immunodeficiency; several transgenic mice develop T-ALL, demonstrating that E2A-HLF disrupts lymphoid development in vivo and requires additional events for full malignant transformation.","method":"Transgenic mouse model (Ig enhancer/promoter-driven E2A-HLF), TUNEL staining, flow cytometry, in vitro colony formation assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — in vivo transgenic model with multiple mechanistic readouts","pmids":["10216071"],"is_preprint":false},{"year":1999,"finding":"Two E2A-HLF downstream target genes were identified: ANNEXIN VIII (upregulated in t(17;19)+ leukemia cells) and SRPUL (a novel sushi-repeat protein); both transcripts decline rapidly within 8–12 hours of E2A-HLF suppression, though neither prevents apoptosis in IL-3-deprived pro-B cells, suggesting paraneoplastic rather than core survival roles.","method":"Representational difference analysis (RDA) of E2A-HLF-active vs. inactive cells, zinc-inducible dominant-negative system","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 — RDA gene identification with inducible system, but downstream functional role not established","pmids":["9864177"],"is_preprint":false},{"year":2001,"finding":"E2A-HLF activates expression of Groucho-related transcriptional corepressors (Grg2, Grg6, and indirectly Grg1, Grg4) 10–50 fold, and downregulates RUNX1 among known Groucho-interacting transcription factors; a DNA-binding-disabled E2A-HLF mutant still mediates pro-B cell survival and activates Groucho genes, suggesting the survival function operates partly through protein-protein interactions independent of direct DNA binding.","method":"Representational difference analysis, zinc-inducible E2A-HLF system in FL5.12 pro-B cells, immunoblot, DNA-binding mutant analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — RDA with inducible system plus mutant dissection establishing pathway position","pmids":["11486032"],"is_preprint":false},{"year":2001,"finding":"CREB is a cellular component of the Ces-2/E2A-HLF binding element (CBE) complex and is part of the IL-3 survival signal; IL-3 stimulation induces CREB phosphorylation at Ser133 partially via PKA; PKA activation prolongs Ba/F3 cell survival in the absence of IL-3; the bcl-2 gene promoter contains functional CRE and CBE sites required for IL-3-inducible expression.","method":"EMSA, in vitro translation/recombinant protein binding, PKA inhibitor/activator experiments, luciferase reporter assays with bcl-2 promoter mutations","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal methods including in vitro binding, pharmacological manipulation, and promoter mutation","pmids":["11416141"],"is_preprint":false},{"year":2001,"finding":"The DBP transcriptional activation domain (TAD) is highly homologous to those of HLF and TEF; deletion of this domain completely abrogates DBP transcriptional activity; the core PAR protein TAD maps to a region of 13 amino acids in HLF (by GAL4-HLF fusion analysis); liver-specific activity is not intrinsic to the TAD but is conferred by other protein regions.","method":"GAL4 fusion deletion analysis, transient transfection reporter assays in multiple cell types, comparative sequence analysis","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 2 — systematic deletion mapping in multiple cell contexts; single lab","pmids":["11223263"],"is_preprint":false},{"year":2002,"finding":"E2A-Hlf expression in bone marrow B-cell progenitors induces short-lived cell clusters without sustained growth; co-expression with Bcl-2 results in sustained self-renewal of pre-B-I cells requiring stromal and IL-7 support, and induces leukemias in irradiated recipients with long latency, demonstrating that E2A-Hlf requires suppression of apoptosis (via Bcl-2) and additional mutations for full leukemogenic conversion.","method":"Retroviral transduction-transplantation, bone marrow stromal co-culture, leukemia transplantation assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — in vivo and in vitro transformation assay with genetic co-expression dissecting requirements","pmids":["12370314"],"is_preprint":false},{"year":2003,"finding":"Annexin II expression in t(17;19)+ leukemia cells is induced by E2A-HLF and is regulated downstream of Ras/PI3K pathways activated by IL-3; E2A-HLF increases annexin II expression in IL-3-deprived cells, effectively substituting for cytokine-activated Ras signaling.","method":"Enforced E2A-HLF expression, cytokine deprivation, Ras pathway inhibitor studies, Western blot","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 3 — single lab, pathway placement by pharmacological inhibition without direct binding evidence","pmids":["15070701"],"is_preprint":false},{"year":2004,"finding":"E4BP4 is a downstream transcriptional target of E2A-HLF in pro-B cells; E2A-HLF acts as a transcriptional activator while E4BP4 acts as a transcriptional repressor at the same DNA binding element (CBE); overexpression of E4BP4 alone cannot block apoptosis from IL-3 withdrawal, distinguishing E2A-HLF's survival function from E4BP4's activity.","method":"Tetracycline-inducible expression system in Baf-3 cells, reporter gene assays, IL-3 withdrawal apoptosis assay","journal":"British journal of haematology","confidence":"Medium","confidence_rationale":"Tier 2–3 — inducible system with reporter assays and functional apoptosis readout; single lab","pmids":["15147370"],"is_preprint":false},{"year":2005,"finding":"TEF (thyrotroph embryonic factor), a PAR bZIP protein related to HLF that recognizes the same DNA sequence, protects IL-3-dependent pro-B cells from apoptosis and uniquely downregulates expression of the common beta chain (βc) of cytokine receptors, causing G0/G1 arrest without apoptosis; in contrast, E2A-HLF promotes survival more efficiently but does not downregulate βc, demonstrating distinct functional properties between the two related proteins.","method":"Retroviral expression in FL5.12 cells, IL-3 withdrawal survival assay, flow cytometry cell cycle analysis, receptor expression analysis","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 — comparative gain-of-function with defined molecular and cellular phenotypes; single lab","pmids":["15665112"],"is_preprint":false},{"year":2006,"finding":"PAR bZIP transcription factors DBP, TEF, and HLF (which accumulate in a circadian manner in liver and kidney) collectively control expression of enzymes and regulators involved in xenobiotic detoxification, including cytochrome P450 enzymes, carboxylesterases, and CAR; triple knockout mice devoid of all three PAR bZIP factors are hypersensitive to xenobiotic compounds.","method":"PAR bZIP triple knockout mouse model, liver/kidney transcriptome comparison, xenobiotic sensitivity assays","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 — genetic triple-knockout with transcriptome profiling and functional xenobiotic phenotype","pmids":["16814730"],"is_preprint":false},{"year":1999,"finding":"HLF and DBP form heterodimers that bind to multiple sites in the Factor VIII and Factor IX promoters with enhanced affinity compared to homodimers; HLF alone and in synergistic combination with DBP transactivates the Factor VIII and Factor IX promoters in HepG2 cells; the E2A-HLF chimera can also mediate expression from these promoters in both hepatoma and pre-B ALL cells.","method":"Transient transfection reporter assays in HepG2 cells, gel mobility shift assay demonstrating heterodimer binding","journal":"DNA and cell biology","confidence":"Medium","confidence_rationale":"Tier 2–3 — gel shift binding plus reporter assays; single lab","pmids":["10073576"],"is_preprint":false},{"year":2009,"finding":"E2A-HLF transcriptionally upregulates Survivin expression throughout the cell cycle in t(17;19)+ ALL cells; Survivin suppression induces massive caspase-independent apoptosis involving AIF translocation from mitochondria to nucleus; AIF knockdown confers resistance to Survivin-loss-induced apoptosis, establishing that E2A-HLF promotes cell survival by maintaining Survivin to prevent AIF-mediated mitochondrial apoptosis.","method":"Dominant-negative E2A-HLF suppression, enforced E2A-HLF expression, reporter assays, counterflow centrifugal elutriation, dominant-negative Survivin, AIF knockdown, cell cycle analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods including gain/loss-of-function, pathway epistasis, and mechanistic validation","pmids":["19887369"],"is_preprint":false},{"year":2010,"finding":"PAR bZIP triple knockout mice (DBP/TEF/HLF-null) develop cardiac hypertrophy and left ventricular dysfunction with low blood pressure, associated with low aldosterone levels and an abnormal cardiovascular response; this demonstrates a role for the PAR bZIP factors including HLF in regulating cardiovascular physiology and aldosterone production.","method":"Triple knockout mouse model, cardiac morphology analysis, blood pressure measurement, aldosterone level measurement","journal":"American journal of physiology. Regulatory, integrative and comparative physiology","confidence":"Medium","confidence_rationale":"Tier 2 — genetic knockout with defined cardiovascular phenotype; confounded by triple KO (cannot attribute to HLF alone)","pmids":["20686175"],"is_preprint":false},{"year":2010,"finding":"E2A-HLF aberrantly induces LMO2 expression through direct binding to a PAR transcription factor binding site in the LMO2 promoter; this induction depends on both the DNA-binding and transactivation activities of E2A-HLF; shRNA-mediated LMO2 silencing in t(17;19)-ALL cells induces apoptosis, establishing LMO2 as a critical E2A-HLF survival target.","method":"Transfection of E2A-HLF into non-t(17;19) ALL cells, promoter reporter assays with PAR-site mutations, shRNA knockdown, apoptosis assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — promoter mutagenesis plus gain-of-function and loss-of-function with functional apoptosis readout","pmids":["20519628"],"is_preprint":false},{"year":2010,"finding":"Retroviral expression of E2A-HLF alone is sufficient to immortalize primary lymphoid progenitors; Lmo2 and Bcl-2 are identified as direct downstream target genes of E2A-HLF; co-expression of Lmo2 and Bcl-2 alone recapitulates E2A-HLF immortalization; shRNA knockdown of Lmo2 or pharmacological BCL-2 inhibition in E2A-HLF-immortalized cells severely compromises viability.","method":"Retroviral expression, real-time PCR in patient biopsies and cell lines, shRNA knockdown, BCL-2 pharmacological inhibition","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal approaches (genetic and pharmacological) with patient sample validation","pmids":["21072044"],"is_preprint":false},{"year":2010,"finding":"Zfp521/ZNF521 was identified as a cooperative gene required with E2A-HLF to develop acute B-lineage leukemia; retroviral insertional mutagenesis in E2A-HLF knock-in mice identified Gfi1, Ikaros, and Zfp521 as common integration sites; tumors with Zfp521 integration exclusively showed B-lineage ALL phenotype; ZNF521 is overexpressed in human t(17;19)-positive leukemic cell lines.","method":"Inducible knock-in mice, retroviral insertional mutagenesis, inverse PCR, ZNF521 expression analysis in human cell lines, double transgenic mice","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic screen with independent validation in human cells and double-transgenic mouse model","pmids":["20062079"],"is_preprint":false},{"year":2012,"finding":"E2A-HLF transcriptionally upregulates death receptors DR4 and DR5 through direct binding to the 5' upstream region of the DR4 gene in a DNA-binding and transactivation-dependent manner; this sensitizes t(17;19)-ALL cells to TRAIL-mediated apoptosis via the extrinsic pathway, providing a potential basis for graft-versus-leukemia effects.","method":"Reporter assays with DR4 promoter regions, enforced E2A-HLF expression in non-t(17;19) cells, recombinant TRAIL apoptosis assay","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2–3 — promoter reporter plus gain-of-function with functional TRAIL sensitivity readout; single lab","pmids":["22743623"],"is_preprint":false},{"year":2015,"finding":"MEIS1 regulates HLF expression in MLL-fusion leukemia (ChIP-seq/gene expression analysis); Meis1 loss leads to increased oxidative stress and apoptosis in leukemic cells; exogenous HLF expression rescues leukemia development in Meis1-deficient cells by reversing the oxidative stress phenotype, placing HLF downstream of MEIS1 in a pathway controlling reactive oxygen species and leukemia maintenance.","method":"Inducible Meis1-knockout mice crossed with MLL-AF9 knock-in, ChIP, gene expression profiling, HLF rescue experiment, oxidative stress measurement","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — ChIP-confirmed target plus genetic epistasis rescue experiment in vivo","pmids":["25740828"],"is_preprint":false},{"year":2015,"finding":"Hlf is a genetic modifier of epilepsy caused by voltage-gated sodium channel mutations; Hlf knockout mice crossed with Scn2a(Q54) epilepsy mice show elevated seizure frequency and reduced survival; dietary pyridoxine deficiency similarly elevates seizures, and Hlf heterozygous knockout worsens survival in Scn1a(KO/+) Dravet syndrome mice, suggesting HLF modifies epilepsy severity through the pyridoxine metabolic pathway.","method":"Hlf targeted knockout mouse model, double mutant crosses with Scn2a(Q54) and Scn1a(KO/+), seizure frequency monitoring, pyridoxine-deficient diet experiment","journal":"Epilepsy research","confidence":"Medium","confidence_rationale":"Tier 2 — genetic modifier analysis with defined phenotype; mechanistic link to pyridoxine pathway is indirect","pmids":["26656780"],"is_preprint":false},{"year":2016,"finding":"TCF3-HLF expression suppresses homologous recombination repair (HRR) activity by decreasing MCPH1 levels, which in turn reduces BRCA1 expression; this HRR deficiency causes synthetic lethality with PARP inhibitors, and olaparib was effective in an in vivo xenograft model of TCF3-HLF-positive leukemia.","method":"HRR activity assay, MCPH1/BRCA1 expression analysis, PARP inhibitor cytotoxicity screening, in vivo xenograft","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic pathway (TCF3-HLF → MCPH1 → BRCA1 → HRR) supported by expression and functional assays","pmids":["27894958"],"is_preprint":false},{"year":2016,"finding":"HLF directly binds to the BS1 site of the miR-132 promoter to enhance miR-132 expression in glioma cells; HLF-mediated miR-132 directly targets and suppresses TTK kinase expression; TTK overexpression reverses the inhibitory effects of miR-132 or HLF on cancer cell proliferation, metastasis, and radioresistance, establishing an HLF→miR-132→TTK axis.","method":"Luciferase reporter assay (miR-132 promoter with BS1 site), lentiviral transduction, wound healing, transwell invasion, clonogenic assay, TTK rescue experiments","journal":"Biomedicine & pharmacotherapy","confidence":"Medium","confidence_rationale":"Tier 2–3 — reporter assay for direct binding plus functional epistasis rescue; single lab","pmids":["27522003"],"is_preprint":false},{"year":2017,"finding":"HLF expression is confined to activated hepatic stellate cells (HSCs) in fibrotic liver; HLF transcriptionally enhances IL-6 expression and intensifies STAT3 phosphorylation to promote HSC activation; conversely, IL-6/STAT3 signaling activates HLF expression, completing a feedforward regulatory circuit; HLF loss impairs primary HSC activation and attenuates liver fibrosis in HLF-knockout mice.","method":"HLF knockout (HLF-PB/PB) mouse model, primary murine HSC isolation and culture, LX2 human HSC line, ectopic HLF expression, IL-6 and p-STAT3 measurement, patient fibrotic liver correlation","journal":"Gut","confidence":"High","confidence_rationale":"Tier 2 — in vivo knockout plus in vitro gain/loss-of-function with defined molecular mechanism (feedforward circuit)","pmids":["28754776"],"is_preprint":false},{"year":2019,"finding":"HLF is an oncofetal protein reactivated in HCC by SOX2 and OCT4; HLF transcriptionally activates c-Jun to promote tumor initiating cell (TIC) generation and TIC-like properties in hepatoma cells; the HLF/c-Jun axis determines sorafenib response, and HLF interference abrogates c-Jun activation and enhances sorafenib sensitivity in patient-derived xenografts.","method":"ChIP/reporter assays for HLF→c-Jun transactivation, in vivo tumor models, patient cohort analysis, PDX sorafenib response","journal":"Gut","confidence":"High","confidence_rationale":"Tier 2 — direct transactivation evidence plus in vivo gain/loss-of-function and PDX validation","pmids":["31118247"],"is_preprint":false},{"year":2019,"finding":"TCF3-HLF recruits HLF binding sites at hematopoietic stem cell/myeloid lineage-associated super-enhancers to drive lineage identity and self-renewal; TCF3-HLF directly activates MYC through hijacking an HLF binding site in a MYC enhancer cluster; TCF3-HLF pioneers cooperation with ERG and recruits histone acetyltransferase EP300, conferring susceptibility to EP300 inhibition.","method":"ChIP-seq of endogenous TCF3-HLF, functional genomics, CRISPRi, EP300 inhibitor treatment, in vivo leukemia propagation assays","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 1–2 — genome-wide ChIP-seq with functional CRISPR validation and in vivo confirmation","pmids":["31735627"],"is_preprint":false},{"year":2019,"finding":"Eya2 is a direct transcriptional target of E2A-HLF, identified by ChIP-qPCR and reporter assay showing E2A-HLF binds the Eya2 promoter consensus sequence; Eya2 is highly expressed in E2A-HLF-immortalized mouse HSPCs; Eya2 knockdown in E2A-HLF-immortalized cells reduces colony-forming efficiency, demonstrating Eya2 is required for E2A-HLF-mediated self-renewal.","method":"ChIP-qPCR, luciferase reporter assay, shRNA knockdown, colony formation assay","journal":"International journal of oncology","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP plus reporter assay plus functional knockdown; single lab","pmids":["30628662"],"is_preprint":false},{"year":2019,"finding":"Hlf expression specifically marks a developmental continuum from HSC precursors to HSCs but not erythro-myeloid progenitors; in the Hlf-tdTomato reporter mouse, Hlf is expressed in intra-aortic hematopoietic clusters and fetal liver HSCs but not in EMPs; HSC specification is regulated by an Evi-1/Hlf axis, active only within Hlf+ nascent hematopoietic clusters.","method":"Hlf-tdTomato knock-in reporter mouse, in vitro co-culture, long-term transplantation assay, Evi-1/Hlf axis characterization","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — reporter mouse with transplantation assay and genetic axis characterization","pmids":["31076455"],"is_preprint":false},{"year":2020,"finding":"HLF downregulation promotes NSCLC metastasis by activating NF-κB/p65 signaling through disrupting nuclear translocation of PPARα and PPARγ, thereby promoting anaerobic metabolism to support anchorage-independent growth under low nutritional conditions; both genetic deletion and methylation contribute to HLF downregulation in NSCLC.","method":"In vivo lung colonization/metastasis models, HLF overexpression/silencing, NF-κB/PPAR localization assays, metabolic assays","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2–3 — in vivo metastasis model with mechanistic pathway characterization; single lab","pmids":["32289442"],"is_preprint":false},{"year":2020,"finding":"miR-98 suppresses hepatic stellate cell activation by directly targeting the 3'UTR of HLF mRNA (confirmed by luciferase reporter assay); HLF overexpression increases HSC activation by inducing HIF-1α expression and activating TGF-β/Smad2/3 signaling; in vivo ago-miR-98 injection attenuates liver fibrosis in multiple murine models and suppresses HLF expression.","method":"Luciferase 3'UTR reporter assay, HLF overexpression, HIF-1α induction, TGF-β/Smad2/3 pathway analysis, in vivo fibrosis models","journal":"Frontiers in cell and developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 — direct 3'UTR binding validated plus pathway characterization in multiple in vivo fibrosis models","pmids":["32637414"],"is_preprint":false},{"year":2021,"finding":"HLF is one of the most specific transcriptional markers of human HSCs; HLF-expressing cells comprise all stem cell activity in culture and during serial transplantation; a genomic HLF reporter strategy selectively labels the most immature blood cells and tracks all hematopoietic stem cell activity, establishing HLF as a defining transcription factor of the human HSC state.","method":"Single-cell and population transcriptomics, genomic HLF reporter (knock-in), serial transplantation assay in vivo","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — reporter mouse with serial transplantation functionally establishing HSC identity","pmids":["34499717"],"is_preprint":false},{"year":2021,"finding":"Hlf-labeled early cells (marked by Hlf-CreER at E9.5) contribute to and retain the HSC pool in adult bone marrow with long-term balanced multilineage hematopoiesis; CD45+ pre-HSCs at E10.5 exist exclusively in the Hlf-tdTomato-positive population, indicating Hlf expression is gained prior to or concurrently with CD45 during HSC specification.","method":"Hlf-tdTomato knock-in reporter, Hlf-CreER lineage tracing (single-dose induction at E9.5), long-term transplantation","journal":"Frontiers in cell and developmental biology","confidence":"High","confidence_rationale":"Tier 2 — lineage tracing with functional HSC transplantation assay","pmids":["34589491"],"is_preprint":false},{"year":2022,"finding":"HLF is regulated by TGF-β1 secreted by tumor-associated macrophages; HLF transactivates GGT1 (gamma-glutamyltransferase 1) to promote ferroptosis resistance, driving TNBC cell proliferation, metastasis, and cisplatin resistance; reciprocally, IL-6 from TNBC cells activates JAK2/STAT3 in macrophages to induce TGF-β1 secretion, constituting a feed-forward IL-6–TGF-β1 circuit sustaining HLF activation.","method":"ChIP/reporter assays for HLF→GGT1 transactivation, ferroptosis assays, TNBC xenograft models, cytokine pathway inhibition","journal":"Journal of hematology & oncology","confidence":"High","confidence_rationale":"Tier 2 — ChIP-confirmed transactivation plus in vivo xenograft with defined pathway circuit","pmids":["34991659"],"is_preprint":false},{"year":2022,"finding":"CircCHD2 functions as a miR-200b-3p sponge, thereby relieving miR-200b-3p-mediated repression of HLF in hepatic stellate cells; enforced HLF expression reverses the suppressive effects of miR-200b-3p overexpression on HSC proliferation and activation markers (α-SMA, Col1A1), placing HLF downstream of the circCHD2/miR-200b-3p axis in liver cirrhosis progression.","method":"Luciferase reporter assay (circCHD2/miR-200b-3p/HLF interactions), TGF-β1-stimulated LX-2 cell model, siRNA knockdown, qPCR/Western blot","journal":"Journal of environmental pathology, toxicology and oncology","confidence":"Medium","confidence_rationale":"Tier 3 — luciferase reporter plus rescue experiments; single lab, cell line only","pmids":["36374958"],"is_preprint":false},{"year":2023,"finding":"HLF activation in intrahepatic cholangiocarcinoma (ICC) is mediated by METTL3-dependent m6A methylation of HLF mRNA; HLF transcriptionally activates FZD4 and FOXQ1; FOXQ1 in turn transcriptionally activates METTL3, forming a positive feedback loop that activates WNT/β-catenin signaling and tumor stemness.","method":"RNA-seq, CUT&Tag (HLF chromatin binding), m6A methylation assay, loss/gain-of-function experiments, METTL3/HLF reporter circuit validation","journal":"Cancer letters","confidence":"High","confidence_rationale":"Tier 1–2 — CUT&Tag for direct binding plus m6A mechanistic validation and feedback loop characterization","pmids":["36958694"],"is_preprint":false},{"year":2023,"finding":"miR-103-3p targets HLF mRNA (validated by luciferase reporter assay); miR-103-3p overexpression promotes apoptosis and inhibits autophagy in HL-1 cardiomyocytes; HLF overexpression reverses this phenotype, inhibiting apoptosis and promoting autophagy, establishing an miR-103-3p/HLF axis regulating cardiomyocyte survival.","method":"Luciferase reporter assay, HL-1 cell transfection, apoptosis assay, autophagy measurement","journal":"ESC heart failure","confidence":"Medium","confidence_rationale":"Tier 2–3 — luciferase reporter validation plus gain/loss-of-function with defined cellular phenotypes; single lab","pmids":["37562973"],"is_preprint":false},{"year":2023,"finding":"HLF transcriptionally activates YAP1 expression in ovarian cancer cells; miR-520e directly targets the HLF 3'UTR (validated by reporter assay); the miR-520e/HLF/YAP1 axis modulates Hippo signaling to regulate ovarian cancer stemness, proliferation, metastasis, and carboplatin resistance.","method":"miR-520e 3'UTR reporter assay, HLF loss/gain-of-function, YAP1 reporter/expression analysis, PDX carboplatin response","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2–3 — reporter assay plus PDX validation; single lab","pmids":["37709768"],"is_preprint":false},{"year":2024,"finding":"HLF expression is epigenetically silenced in metastatic ccRCC by the SWI/SNF ATPase subunit BRG1; HLF suppresses lung metastasis by regulating LPXN (leupaxin) expression, which modulates integration of collagen mechanical cues with the actin cytoskeleton through Paxillin; BRG1 inhibition restores HLF expression and reduces cell invasion across multiple cancer types.","method":"In vivo CRISPR-Cas9 genome-wide screen, HLF overexpression/depletion in ccRCC migration/metastasis assays, BRG1 ChIP/epigenetic silencing analysis, LPXN/Paxillin pathway characterization","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 — in vivo CRISPR screen plus mechanistic pathway characterization with epigenetic regulation","pmids":["40473600"],"is_preprint":false},{"year":2024,"finding":"HLF efficiently marks HSC-fated artery endothelial cells during a narrow developmental window; guided by arterial HSC origins, hPSC differentiation through artery endothelium rapidly generates >90% pure HLF+HOXA+ hematopoietic progenitors within 10 days that express hallmark HSC transcription factors and generate multiple blood lineages.","method":"Non-invasive genetic lineage tracing in mouse embryos, hPSC stepwise differentiation protocol with defined media, single-cell profiling, in vitro multilineage differentiation","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 2 — in vivo lineage tracing plus functional hPSC differentiation with HLF as HSC identity marker","pmids":["38569552"],"is_preprint":false},{"year":2025,"finding":"HLF transcriptionally activates TFEB and IL-6R as direct target genes in gallbladder cancer stem cells; the IL-6/IL-6R/STAT3 axis transactivates HLF forming a positive feedback loop; HLF promotes cancer stem cell expansion and gemcitabine resistance via TFEB-induced autophagy; HLF also drives TFEB-induced PD-L1 expression to govern CD8+ T cell-dependent immune evasion.","method":"ChIP/CUT&Tag for HLF→TFEB/IL-6R binding, luciferase reporter assays, in vivo xenograft/PDX models, CD8+ T cell depletion experiments","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 1–2 — CUT&Tag direct binding evidence with in vivo validation of multiple downstream mechanisms","pmids":["40779629"],"is_preprint":false},{"year":2025,"finding":"Bmi1 represses HLF by directly binding to its promoter (validated by luciferase reporter assay) in intrahepatic cholangiocarcinoma; HLF overexpression inhibits ICC growth in vitro and in vivo; HLF repression reverses the inhibitory effects of Bmi1 knockdown on cell survival and proliferation, establishing HLF as a tumor suppressor downstream of Bmi1 in ICC.","method":"RNA-seq, luciferase reporter assay (Bmi1 binding to HLF promoter), lentiviral overexpression/knockout, xenograft and primary ICC mouse models","journal":"British journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 — reporter assay for direct binding plus in vivo functional validation; single lab","pmids":["41136715"],"is_preprint":false},{"year":2025,"finding":"HLF transcriptionally activates SLC7A11 to inhibit trophoblast ferroptosis; WTAP-dependent m6A methylation stabilizes HLF mRNA; WTAP downregulation in preeclampsia reduces HLF levels, leading to reduced SLC7A11 expression and increased ferroptosis in trophoblasts, impairing their proliferation, migration, and invasion.","method":"Reporter assays for HLF→SLC7A11 transactivation, m6A methylation analysis, WTAP knockdown, ferroptosis assays, trophoblast functional assays","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2–3 — transactivation reporter plus m6A mechanistic link; single lab","pmids":["40827901"],"is_preprint":false},{"year":2025,"finding":"HLF and hTERT co-overexpression in human HSPCs enables partial immortalization (up to 70 days in culture) with limited differentiation capacity; HLF alone (as a stem cell maintenance regulator) is insufficient without hTERT-mediated telomere maintenance, and the combination maintains HSPC identity markers.","method":"Lentiviral co-overexpression, BaEV-mediated transduction, long-term culture, lineage differentiation assays","journal":"Frontiers in bioengineering and biotechnology","confidence":"Medium","confidence_rationale":"Tier 2–3 — functional co-expression experiment; single lab, partial immortalization only","pmids":["41602466"],"is_preprint":false}],"current_model":"HLF (hepatic leukemia factor) is a PAR-subfamily bZIP transcription factor that binds the consensus sequence 5'-GTTACGTAAT-3' as a homodimer or heterodimer with DBP/TEF, activates target genes through a conserved ~13–40 amino acid transactivation domain (THAD), and functions in circadian-regulated xenobiotic detoxification, HSC identity/self-renewal (operating downstream of MEIS1 and in an Evi-1/HLF axis), and tissue-specific gene regulation (Factor VIII/IX, HBV enhancer II, cholesterol 7α-hydroxylase, albumin); in the oncogenic E2A-HLF fusion arising from t(17;19) translocation, the E2A transactivation domains drive leukemogenesis by activating survival genes (SLUG, LMO2, Survivin, Groucho-related corepressors, Eya2) and blocking apoptosis downstream of p53 through homodimeric DNA binding, while in non-leukemic contexts HLF suppresses metastasis via LPXN/Paxillin-mediated cytoskeletal regulation (epigenetically silenced by BRG1), promotes liver fibrosis through a HLF/IL-6/STAT3 feedforward circuit in hepatic stellate cells, and drives cancer progression by transactivating c-Jun, GGT1, YAP1, FZD4, TFEB, and IL-6R depending on cellular context."},"narrative":{"teleology":[{"year":1992,"claim":"Cloning of HLF revealed it as a PAR bZIP transcription factor and identified the t(17;19)-generated E2A-HLF chimera as the molecular basis of a subset of B-lineage ALL, establishing the gene's dual identity in normal tissue-specific transcription and leukemogenesis.","evidence":"Molecular cloning, Northern blot, chimeric transcript sequencing, gel mobility shift assays showing homodimeric and heterodimeric DNA binding","pmids":["1386162","1516826"],"confidence":"High","gaps":["Wild-type HLF function in hematopoiesis unknown","Downstream targets of E2A-HLF unidentified","Structural basis of dimerization preference unresolved"]},{"year":1995,"claim":"Characterization of the HLF consensus binding site (5'-GTTACGTAAT-3'), identification of two isoforms from alternative promoters with distinct circadian amplitudes and target gene preferences, and mapping of the conserved THAD transactivation domain established the molecular toolkit for HLF-mediated transcription.","evidence":"In vitro binding site selection, reporter assays across cell types, alternative promoter mapping with CUG initiation, GAL4 fusion deletion analysis","pmids":["8065331","7556072","8639829"],"confidence":"High","gaps":["Crystal structure of HLF bZIP domain lacking","Cofactors recruited by THAD unknown","Chromatin-level target gene regulation not explored"]},{"year":1996,"claim":"Demonstration that E2A-HLF blocks apoptosis (both IL-3 withdrawal and p53-mediated) rather than promoting proliferation resolved a fundamental question about the oncogenic mechanism, showing the chimera sustains cell survival.","evidence":"Dominant-negative E2A-HLF suppression in t(17;19) leukemia cells, IL-3 deprivation and p53-mediated apoptosis assays in pro-B cells","pmids":["8700228"],"confidence":"High","gaps":["Downstream survival effectors of E2A-HLF not yet identified","Mechanism by which survival is uncoupled from growth unclear"]},{"year":1999,"claim":"Identification of SLUG as an E2A-HLF-activated antiapoptotic effector, demonstration that E2A-HLF transforms through homodimeric (gain-of-function) rather than dominant-negative binding, and in vivo transgenic modeling showing E2A-HLF disrupts lymphoid development requiring additional cooperating events, collectively defined the leukemogenic pathway.","evidence":"SLUG identification and IL-3 withdrawal rescue, leucine zipper mutagenesis separating homo- from heterodimer function, E2A-HLF transgenic mouse with lymphoid defects and T-ALL","pmids":["10518215","9032268","10216071"],"confidence":"High","gaps":["Direct promoter binding by E2A-HLF to SLUG not shown","Full repertoire of cooperating mutations unknown","Wild-type HLF role in normal B-cell development unaddressed"]},{"year":2001,"claim":"Discovery that E2A-HLF activates Groucho-related corepressors and can function through protein-protein interactions independent of direct DNA binding expanded the mechanistic model beyond simple sequence-specific transactivation.","evidence":"RDA in zinc-inducible FL5.12 pro-B cell system, DNA-binding-disabled E2A-HLF mutant retaining survival activity","pmids":["11486032"],"confidence":"High","gaps":["Identity of protein partners mediating DNA-binding-independent activity unknown","Groucho targets downstream of E2A-HLF not defined"]},{"year":2006,"claim":"Triple knockout of all three PAR bZIP factors (DBP/TEF/HLF) revealed their collective role in circadian xenobiotic detoxification, providing the first in vivo physiological function for HLF outside of hematopoiesis and cancer.","evidence":"PAR bZIP triple knockout mouse with liver/kidney transcriptome profiling and xenobiotic hypersensitivity","pmids":["16814730"],"confidence":"High","gaps":["Individual contribution of HLF vs. DBP vs. TEF to detoxification gene regulation unresolved","Cardiovascular phenotype later found in triple KO not yet attributed to specific PAR factor"]},{"year":2010,"claim":"Identification of LMO2 and BCL-2 as direct E2A-HLF targets whose combined expression recapitulates E2A-HLF immortalization, and ZNF521 as a cooperating gene, defined the minimal oncogenic circuitry for E2A-HLF-driven B-ALL.","evidence":"ChIP/reporter for LMO2, shRNA and pharmacological BCL-2 inhibition, retroviral insertional mutagenesis identifying ZNF521 in E2A-HLF knock-in mice","pmids":["20519628","21072044","20062079"],"confidence":"High","gaps":["Whether LMO2/BCL-2 sufficiency applies in human primary leukemia cells untested","Mechanism of ZNF521 cooperation with E2A-HLF unclear"]},{"year":2015,"claim":"Placing HLF downstream of MEIS1 in MLL-fusion leukemia, where HLF rescues oxidative stress and leukemia maintenance in Meis1-deficient cells, established HLF as a functional effector of the MEIS1-dependent stem cell program beyond the t(17;19) context.","evidence":"Inducible Meis1 knockout crossed with MLL-AF9 knock-in, ChIP-confirmed MEIS1 binding to HLF locus, HLF rescue of leukemia in vivo","pmids":["25740828"],"confidence":"High","gaps":["Direct transcriptional targets of wild-type HLF in leukemia maintenance undefined","Whether HLF regulates ROS through xenobiotic enzymes or other pathways unknown"]},{"year":2017,"claim":"Discovery of the HLF/IL-6/STAT3 feedforward circuit in hepatic stellate cells, validated by HLF-knockout mice with attenuated fibrosis, established the first non-hematopoietic, non-circadian disease mechanism for wild-type HLF.","evidence":"HLF-knockout mouse model, primary HSC isolation, LX2 human HSC line, HLF gain/loss-of-function with IL-6/STAT3 pathway measurement","pmids":["28754776"],"confidence":"High","gaps":["Direct HLF binding sites on the IL-6 promoter not mapped by ChIP-seq","Whether HLF has roles in other fibrotic organs beyond liver unknown"]},{"year":2019,"claim":"Genome-wide ChIP-seq of endogenous TCF3-HLF revealed it hijacks HLF binding sites at HSC/myeloid super-enhancers to activate MYC and cooperates with ERG and EP300, while parallel studies showed HLF marks the entire HSC developmental continuum from arterial endothelium through the Evi-1/HLF axis, unifying the fusion oncogene's mechanism with normal HSC biology.","evidence":"ChIP-seq, CRISPRi, EP300 inhibitor treatment, Hlf-tdTomato knock-in reporter mouse, in vivo transplantation, Evi-1/Hlf axis characterization","pmids":["31735627","31076455","31118247"],"confidence":"High","gaps":["Whether EP300 inhibitors have therapeutic efficacy in patients with t(17;19) ALL untested","How HLF binding site specificity differs between HSCs and leukemia cells unresolved"]},{"year":2021,"claim":"Genomic HLF reporter strategies and lineage tracing in human and mouse systems confirmed HLF as one of the most specific transcriptional markers defining HSC identity, with HLF+ cells comprising all long-term repopulating stem cell activity.","evidence":"HLF-tdTomato reporter, HLF-CreER lineage tracing at E9.5, serial transplantation, single-cell transcriptomics","pmids":["34499717","34589491"],"confidence":"High","gaps":["Functional consequences of HLF loss specifically in adult HSCs (single-gene knockout) not reported","Whether HLF is instructive or merely correlative for HSC identity unresolved"]},{"year":2022,"claim":"In solid tumors, HLF was shown to transactivate GGT1 to confer ferroptosis resistance in TNBC downstream of macrophage-derived TGF-β1 signaling, revealing a cancer-type-specific mechanism distinct from its leukemic or hepatic roles.","evidence":"ChIP/reporter for HLF→GGT1, ferroptosis assays, TNBC xenograft with cytokine pathway inhibition","pmids":["34991659"],"confidence":"High","gaps":["Whether HLF-mediated ferroptosis resistance is generalizable to other cancer types unknown","Direct structural basis of HLF target gene selectivity across tissues unresolved"]},{"year":2024,"claim":"An in vivo CRISPR screen identified HLF as a metastasis suppressor in ccRCC, epigenetically silenced by BRG1, that restrains invasion through LPXN/Paxillin-mediated cytoskeletal regulation, establishing a tumor-suppressive role directly opposing its oncogenic functions in other contexts.","evidence":"Genome-wide in vivo CRISPR screen, HLF overexpression/depletion in metastasis assays, BRG1 ChIP, LPXN/Paxillin pathway characterization","pmids":["40473600"],"confidence":"High","gaps":["How the same transcription factor acts as oncogene vs. tumor suppressor in different tissues remains mechanistically unexplained","Whether BRG1-mediated silencing of HLF occurs in cancers beyond ccRCC untested"]},{"year":2025,"claim":"Identification of TFEB and IL-6R as direct HLF targets in gallbladder cancer stem cells, driving autophagy-dependent drug resistance and PD-L1-mediated immune evasion, extended HLF's target repertoire to immune-modulatory and autophagy pathways.","evidence":"CUT&Tag/ChIP for HLF→TFEB/IL-6R, xenograft/PDX models, CD8+ T cell depletion experiments","pmids":["40779629"],"confidence":"High","gaps":["Whether HLF-TFEB axis operates in non-cancer stem cells unknown","Therapeutic targeting of HLF itself remains unexplored"]},{"year":null,"claim":"Key unresolved questions include: how HLF exerts opposing oncogenic versus tumor-suppressive functions across tissue contexts, what the functional consequences of isolated HLF loss are in adult HSCs, and whether HLF can be directly targeted therapeutically.","evidence":"","pmids":[],"confidence":"Low","gaps":["No conditional single-gene HLF knockout in adult HSCs reported","No crystal structure of HLF bZIP domain available","Tissue-specific cofactor interactions determining target gene selectivity uncharacterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,1,2,6]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[3,6,17,34,35,43,45,47,50]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[8]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[3,6,17,34,35,45,50]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[34,43,45,50]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[5,10,12,24,26,27]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[38,41,42,49]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,4,13,28,36]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[50]}],"complexes":[],"partners":["DBP","TEF","E2A","MEIS1","ERG","EP300","STAT3"],"other_free_text":[]},"mechanistic_narrative":"HLF is a PAR-subfamily basic leucine zipper (bZIP) transcription factor that binds the consensus sequence 5'-GTTACGTAAT-3' as a homodimer or heterodimer with DBP and TEF, activating target genes through a highly conserved transactivation domain (THAD) in liver, kidney, brain, and hematopoietic stem cells [PMID:1386162, PMID:8065331, PMID:7556072, PMID:8639829]. In normal physiology, HLF marks and maintains hematopoietic stem cell identity from embryonic specification onward, operates downstream of MEIS1 and within an Evi-1/HLF axis to control HSC self-renewal and oxidative stress resistance, and cooperates with DBP and TEF to drive circadian xenobiotic detoxification in liver and kidney [PMID:34499717, PMID:31076455, PMID:25740828, PMID:16814730]. In disease contexts, HLF promotes hepatic stellate cell activation and liver fibrosis through an HLF/IL-6/STAT3 feedforward circuit, transactivates diverse oncogenic targets (c-Jun, GGT1, YAP1, FZD4, TFEB, IL-6R) in solid tumors, and suppresses metastasis in ccRCC via LPXN/Paxillin-mediated cytoskeletal regulation when not epigenetically silenced by BRG1 [PMID:28754776, PMID:31118247, PMID:34991659, PMID:40473600, PMID:40779629]. The t(17;19) chromosomal translocation fuses E2A transactivation domains to the HLF bZIP domain, creating the E2A-HLF oncoprotein that drives B-lineage acute lymphoblastic leukemia by blocking apoptosis downstream of p53 and activating survival targets including SLUG, LMO2, Survivin, and MYC through hijacking of HLF-bound enhancers [PMID:1386162, PMID:8700228, PMID:10518215, PMID:20519628, PMID:31735627]."},"prefetch_data":{"uniprot":{"accession":"Q16534","full_name":"Hepatic leukemia factor","aliases":[],"length_aa":295,"mass_kda":33.2,"function":"","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q16534/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/HLF","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/HLF","total_profiled":1310},"omim":[{"mim_id":"612399","title":"TLE FAMILY MEMBER 6, SUBCORTICAL MATERNAL COMPLEX MEMBER; TLE6","url":"https://www.omim.org/entry/612399"},{"mim_id":"605074","title":"RENAL CELL CARCINOMA, PAPILLARY, 1; RCCP1","url":"https://www.omim.org/entry/605074"},{"mim_id":"602396","title":"ANNEXIN A8; ANXA8","url":"https://www.omim.org/entry/602396"},{"mim_id":"602150","title":"SNAIL FAMILY TRANSCRIPTIONAL REPRESSOR 2; SNAI2","url":"https://www.omim.org/entry/602150"},{"mim_id":"300642","title":"SUSHI REPEAT-CONTAINING PROTEIN, X-LINKED, 2; SRPX2","url":"https://www.omim.org/entry/300642"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"liver","ntpm":114.4}],"url":"https://www.proteinatlas.org/search/HLF"},"hgnc":{"alias_symbol":["MGC33822"],"prev_symbol":[]},"alphafold":{"accession":"Q16534","domains":[{"cath_id":"-","chopping":"171-208_216-291","consensus_level":"high","plddt":95.1226,"start":171,"end":291}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q16534","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q16534-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q16534-F1-predicted_aligned_error_v6.png","plddt_mean":71.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=HLF","jax_strain_url":"https://www.jax.org/strain/search?query=HLF"},"sequence":{"accession":"Q16534","fasta_url":"https://rest.uniprot.org/uniprotkb/Q16534.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q16534/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q16534"}},"corpus_meta":[{"pmid":"10202154","id":"PMC_10202154","title":"Molecular mechanisms of transcription activation by HLF and HIF1alpha in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300.","date":"1999","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/10202154","citation_count":491,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16814730","id":"PMC_16814730","title":"The circadian PAR-domain basic leucine zipper transcription factors DBP, TEF, and HLF modulate basal and inducible xenobiotic detoxification.","date":"2006","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/16814730","citation_count":400,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1386162","id":"PMC_1386162","title":"Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-lineage leukemia.","date":"1992","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/1386162","citation_count":271,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34991659","id":"PMC_34991659","title":"HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk.","date":"2022","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34991659","citation_count":215,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1516826","id":"PMC_1516826","title":"Hlf, a novel hepatic bZIP protein, shows altered DNA-binding properties following fusion to E2A in t(17;19) acute lymphoblastic leukemia.","date":"1992","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/1516826","citation_count":214,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26214592","id":"PMC_26214592","title":"Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options.","date":"2015","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26214592","citation_count":196,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12606578","id":"PMC_12606578","title":"HLF/HIF-2alpha is a key factor in retinopathy of prematurity in association with erythropoietin.","date":"2003","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/12606578","citation_count":194,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28754776","id":"PMC_28754776","title":"The HLF/IL-6/STAT3 feedforward circuit drives hepatic stellate cell activation to promote liver fibrosis.","date":"2017","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/28754776","citation_count":188,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10518215","id":"PMC_10518215","title":"SLUG, a ces-1-related zinc finger transcription factor gene with antiapoptotic activity, is a downstream target of the E2A-HLF oncoprotein.","date":"1999","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/10518215","citation_count":171,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8700228","id":"PMC_8700228","title":"Reversal of apoptosis by the leukaemia-associated E2A-HLF chimaeric transcription factor.","date":"1996","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8700228","citation_count":118,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9704006","id":"PMC_9704006","title":"Transcriptionally active heterodimer formation of an Arnt-like PAS protein, Arnt3, with HIF-1a, HLF, and clock.","date":"1998","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9704006","citation_count":117,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31118247","id":"PMC_31118247","title":"Oncofetal HLF transactivates c-Jun to promote hepatocellular carcinoma development and sorafenib resistance.","date":"2019","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/31118247","citation_count":109,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7556072","id":"PMC_7556072","title":"The rat hepatic leukemia factor (HLF) gene encodes two transcriptional activators with distinct circadian rhythms, tissue distributions and target preferences.","date":"1995","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/7556072","citation_count":92,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17183364","id":"PMC_17183364","title":"Hypercalcemia in childhood acute lymphoblastic leukemia: frequent implication of parathyroid hormone-related peptide and E2A-HLF from translocation 17;19.","date":"2006","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/17183364","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32289442","id":"PMC_32289442","title":"Downregulation of the circadian rhythm regulator HLF promotes multiple-organ distant metastases in non-small cell lung cancer through PPAR/NF-κb signaling.","date":"2020","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/32289442","citation_count":74,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34499717","id":"PMC_34499717","title":"HLF expression defines the human hematopoietic stem cell state.","date":"2021","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/34499717","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31076455","id":"PMC_31076455","title":"Hlf marks the developmental pathway for hematopoietic stem cells but not for erythro-myeloid progenitors.","date":"2019","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31076455","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20686175","id":"PMC_20686175","title":"Cardiac hypertrophy, low blood pressure, and low aldosterone levels in mice devoid of the three circadian PAR bZip transcription factors DBP, HLF, and TEF.","date":"2010","source":"American journal of physiology. Regulatory, integrative and comparative physiology","url":"https://pubmed.ncbi.nlm.nih.gov/20686175","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16707273","id":"PMC_16707273","title":"Functional role of DMT1 in transferrin-independent iron uptake by human hepatocyte and hepatocellular carcinoma cell, HLF.","date":"2006","source":"Hepatology research : the official journal of the Japan Society of Hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/16707273","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27522003","id":"PMC_27522003","title":"HLF/miR-132/TTK axis regulates cell proliferation, metastasis and radiosensitivity of glioma cells.","date":"2016","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/27522003","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8065331","id":"PMC_8065331","title":"DNA-binding and transcriptional regulatory properties of hepatic leukemia factor (HLF) and the t(17;19) acute lymphoblastic leukemia chimera E2A-HLF.","date":"1994","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8065331","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10627534","id":"PMC_10627534","title":"Identification of multiple transcription factors, HLF, FTF, and E4BP4, controlling hepatitis B virus enhancer II.","date":"2000","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/10627534","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31735627","id":"PMC_31735627","title":"The Leukemogenic TCF3-HLF Complex Rewires Enhancers Driving Cellular Identity and Self-Renewal Conferring EP300 Vulnerability.","date":"2019","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/31735627","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8180393","id":"PMC_8180393","title":"Two types of genomic rearrangements create alternative E2A-HLF fusion proteins in t(17;19)-ALL.","date":"1994","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/8180393","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9864177","id":"PMC_9864177","title":"Two candidate downstream target genes for E2A-HLF.","date":"1999","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9864177","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7760820","id":"PMC_7760820","title":"E2A-HLF-mediated cell transformation requires both the trans-activation domains of E2A and the leucine zipper dimerization domain of HLF.","date":"1995","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7760820","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9398602","id":"PMC_9398602","title":"Cardiac expressions of HIF-1 alpha and HLF/EPAS, two basic loop helix/PAS domain transcription factors involved in adaptative responses to hypoxic stresses.","date":"1997","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9398602","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11486032","id":"PMC_11486032","title":"The E2A-HLF oncoprotein activates Groucho-related genes and suppresses Runx1.","date":"2001","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11486032","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20062079","id":"PMC_20062079","title":"Identification of Zfp521/ZNF521 as a cooperative gene for E2A-HLF to develop acute B-lineage leukemia.","date":"2010","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/20062079","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9694729","id":"PMC_9694729","title":"The chimeric E2A-HLF transcription factor abrogates p53-induced apoptosis in myeloid leukemia cells.","date":"1998","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9694729","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11416141","id":"PMC_11416141","title":"CREB is one component of the binding complex of the Ces-2/E2A-HLF binding element and is an integral part of the interleukin-3 survival signal.","date":"2001","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11416141","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26656780","id":"PMC_26656780","title":"Hlf is a genetic modifier of epilepsy caused by voltage-gated sodium channel mutations.","date":"2015","source":"Epilepsy research","url":"https://pubmed.ncbi.nlm.nih.gov/26656780","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20519628","id":"PMC_20519628","title":"Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(17;19).","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20519628","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38569552","id":"PMC_38569552","title":"Lineage-tracing hematopoietic stem cell origins in vivo to efficiently make human HLF+ HOXA+ hematopoietic progenitors from pluripotent stem cells.","date":"2024","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/38569552","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21072044","id":"PMC_21072044","title":"The E2A-HLF oncogenic fusion protein acts through Lmo2 and Bcl-2 to immortalize hematopoietic progenitors.","date":"2010","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/21072044","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9742120","id":"PMC_9742120","title":"The AD1 and AD2 transactivation domains of E2A are essential for the antiapoptotic activity of the chimeric oncoprotein E2A-HLF.","date":"1998","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9742120","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10216071","id":"PMC_10216071","title":"Expression of E2A-HLF chimeric protein induced T-cell apoptosis, B-cell maturation arrest, and development of acute lymphoblastic leukemia.","date":"1999","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/10216071","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8639829","id":"PMC_8639829","title":"The proto-oncogene HLF and the related basic leucine zipper protein TEF display highly similar DNA-binding and transcriptional regulatory properties.","date":"1996","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/8639829","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32637414","id":"PMC_32637414","title":"MicroRNA-98 Inhibits Hepatic Stellate Cell Activation and Attenuates Liver Fibrosis by Regulating HLF Expression.","date":"2020","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/32637414","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9032268","id":"PMC_9032268","title":"Cell transformation mediated by homodimeric E2A-HLF transcription factors.","date":"1997","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9032268","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28571757","id":"PMC_28571757","title":"HMGB1 promotes HLF-1 proliferation and ECM production through activating HIF1-α-regulated aerobic glycolysis.","date":"2017","source":"Pulmonary pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/28571757","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10330184","id":"PMC_10330184","title":"Disrupted differentiation and oncogenic transformation of lymphoid progenitors in E2A-HLF transgenic mice.","date":"1999","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10330184","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25740828","id":"PMC_25740828","title":"MEIS1 regulates an HLF-oxidative stress axis in MLL-fusion gene leukemia.","date":"2015","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/25740828","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11607821","id":"PMC_11607821","title":"E2A-HLF usurps control of evolutionarily conserved survival pathways.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11607821","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27894958","id":"PMC_27894958","title":"Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells.","date":"2016","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/27894958","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15665112","id":"PMC_15665112","title":"TEF, an antiapoptotic bZIP transcription factor related to the oncogenic E2A-HLF chimera, inhibits cell growth by down-regulating expression of the common beta chain of cytokine receptors.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15665112","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36958694","id":"PMC_36958694","title":"m6A RNA methylation-mediated upregulation of HLF promotes intrahepatic cholangiocarcinoma progression by regulating the FZD4/β-catenin signaling pathway.","date":"2023","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/36958694","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29409862","id":"PMC_29409862","title":"The antimicrobial cathelicidin peptide hlF(1-11) attenuates alveolar macrophage pyroptosis induced by Acinetobacter baumannii in vivo.","date":"2018","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/29409862","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12370314","id":"PMC_12370314","title":"Transformation of bone marrow B-cell progenitors by E2a-Hlf requires coexpression of Bcl-2.","date":"2002","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12370314","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15070701","id":"PMC_15070701","title":"Regulation of annexin II by cytokine-initiated signaling pathways and E2A-HLF oncoprotein.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15070701","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25776104","id":"PMC_25776104","title":"Effects of fucoidan on proliferation, AMP-activated protein kinase, and downstream metabolism- and cell cycle-associated molecules in poorly differentiated human hepatoma HLF cells.","date":"2015","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25776104","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23181981","id":"PMC_23181981","title":"A novel TCF3-HLF fusion transcript in acute lymphoblastic leukemia with a t(17;19)(q22;p13).","date":"2012","source":"Cancer genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23181981","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24284116","id":"PMC_24284116","title":"Optimizing the antitumor selectivity of PVP-Hypericin re A549 cancer cells and HLF normal cells through pulsed blue light.","date":"2013","source":"Photodiagnosis and photodynamic therapy","url":"https://pubmed.ncbi.nlm.nih.gov/24284116","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37709768","id":"PMC_37709768","title":"HLF promotes ovarian cancer progression and chemoresistance via regulating Hippo signaling pathway.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/37709768","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22743623","id":"PMC_22743623","title":"Oncogenic fusion E2A-HLF sensitizes t(17;19)-positive acute lymphoblastic leukemia to TRAIL-mediated apoptosis by upregulating the expression of death receptors.","date":"2012","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/22743623","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16206189","id":"PMC_16206189","title":"ABCB1 over-expression and drug-efflux in acute lymphoblastic leukemia cell lines with t(17;19) and E2A-HLF expression.","date":"2006","source":"Pediatric blood & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16206189","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19219636","id":"PMC_19219636","title":"A mWAP-hLF hybrid gene locus gave extremely high level expression of human lactoferrin in the milk of transgenic mice.","date":"2009","source":"Transgenic research","url":"https://pubmed.ncbi.nlm.nih.gov/19219636","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10504033","id":"PMC_10504033","title":"Characteristics of L-carnitine transport in cultured human hepatoma HLF cells.","date":"1999","source":"The Journal of pharmacy and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/10504033","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11223263","id":"PMC_11223263","title":"The DBP transcriptional activation domain is highly homologous to that of HLF and TEF and is not responsible for the tissue type-specific transcriptional activity of DBP.","date":"2001","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/11223263","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34589491","id":"PMC_34589491","title":"Hlf Expression Marks Early Emergence of Hematopoietic Stem Cell Precursors With Adult Repopulating Potential and Fate.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34589491","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33640284","id":"PMC_33640284","title":"Successful Treatment of TCF3-HLF-positive Childhood B-ALL with Chimeric Antigen Receptor T-Cell Therapy.","date":"2021","source":"Clinical lymphoma, myeloma & leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/33640284","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37562973","id":"PMC_37562973","title":"miRNA-103-3p-Hlf regulates apoptosis and autophagy by targeting hepatic leukaemia factor in heart failure.","date":"2023","source":"ESC heart failure","url":"https://pubmed.ncbi.nlm.nih.gov/37562973","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36551443","id":"PMC_36551443","title":"In Vitro Antimycobacterial Activity of Human Lactoferrin-Derived Peptide, D-hLF 1-11, against Susceptible and Drug-Resistant Mycobacterium tuberculosis and Its Synergistic Effect with Rifampicin.","date":"2022","source":"Antibiotics (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/36551443","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16531271","id":"PMC_16531271","title":"Characterization of the t(17;19) translocation by gene-specific fluorescent in situ hybridization-based cytogenetics and detection of the E2A-HLF fusion transcript and protein in patients' cells.","date":"2006","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/16531271","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34876631","id":"PMC_34876631","title":"FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/34876631","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10073576","id":"PMC_10073576","title":"Enhanced binding of HLF/DBP heterodimers represents one mechanism of PAR protein transactivation of the factor VIII and factor IX genes.","date":"1999","source":"DNA and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/10073576","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29334255","id":"PMC_29334255","title":"NGS-based methylation profiling differentiates TCF3-HLF and TCF3-PBX1 positive B-cell acute lymphoblastic leukemia.","date":"2018","source":"Epigenomics","url":"https://pubmed.ncbi.nlm.nih.gov/29334255","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9366523","id":"PMC_9366523","title":"The chimeric oncoproteins E2A-PBX1 and E2A-HLF are concentrated within spherical nuclear domains.","date":"1997","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9366523","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19887369","id":"PMC_19887369","title":"Up-regulation of survivin by the E2A-HLF chimera is indispensable for the survival of t(17;19)-positive leukemia cells.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19887369","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33880339","id":"PMC_33880339","title":"The advantage of chimeric antigen receptor T cell therapy in pediatric acute lymphoblastic leukemia with E2A-HLF fusion gene positivity: a case series.","date":"2021","source":"Translational pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/33880339","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36374958","id":"PMC_36374958","title":"CircCHD2/miR-200b-3p/HLF Axis Promotes Liver Cirrhosis.","date":"2022","source":"Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36374958","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40236774","id":"PMC_40236774","title":"HLF and PPARα axis regulates metabolic-associated fatty liver disease through extracellular vesicles derived from the intestinal microbiota.","date":"2025","source":"iMeta","url":"https://pubmed.ncbi.nlm.nih.gov/40236774","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33099483","id":"PMC_33099483","title":"Genetic Analysis Identifies the Role of HLF in Renal Cell Carcinoma.","date":"2020","source":"Cancer genomics & proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/33099483","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15147370","id":"PMC_15147370","title":"E4BP4 expression is regulated by the t(17;19)-associated oncoprotein E2A-HLF in pro-B cells.","date":"2004","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/15147370","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12111652","id":"PMC_12111652","title":"E2A/HLF fusion gene in an acute lymphoblastic leukemia patient with disseminated intravascular coagulation and a normal karyotype.","date":"2002","source":"The hematology journal : the official journal of the European Haematology Association","url":"https://pubmed.ncbi.nlm.nih.gov/12111652","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26588248","id":"PMC_26588248","title":"Conditional Expression of E2A-HLF Induces B-Cell Precursor Death and Myeloproliferative-Like Disease in Knock-In Mice.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26588248","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32245383","id":"PMC_32245383","title":"Comprehensive chromosomal aberrations in a case of a patient with TCF3-HLF-positive BCP-ALL.","date":"2020","source":"BMC medical genomics","url":"https://pubmed.ncbi.nlm.nih.gov/32245383","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32391417","id":"PMC_32391417","title":"Targeting the oncogenic activity of TCF3-HLF in leukemia.","date":"2020","source":"Molecular & cellular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32391417","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28627280","id":"PMC_28627280","title":"The targeting effect of Hm2E8b-NCTD-liposomes on B-lineage leukaemia stem cells is associated with the HLF-SLUG axis.","date":"2017","source":"Journal of drug targeting","url":"https://pubmed.ncbi.nlm.nih.gov/28627280","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31661123","id":"PMC_31661123","title":"The goat β‑casein/CMV chimeric promoter drives the expression of hLF in transgenic goats produced by cell transgene microinjection.","date":"2019","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31661123","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35573697","id":"PMC_35573697","title":"Co-Expression of Runx1, Hoxa9, Hlf, and Hoxa7 Confers Multi-Lineage Potential on Hematopoietic Progenitors Derived From Pluripotent Stem Cells.","date":"2022","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/35573697","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9571207","id":"PMC_9571207","title":"Regulation of the DBP promoter by PAR proteins and in leukemic cells bearing an E2A/HLF translocation.","date":"1998","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9571207","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39200089","id":"PMC_39200089","title":"Combinatory Use of hLF(1-11), a Synthetic Peptide Derived from Human Lactoferrin, and Fluconazole/Amphotericin B against Malassezia furfur Reveals a Synergistic/Additive Antifungal Effect.","date":"2024","source":"Antibiotics (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/39200089","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40779629","id":"PMC_40779629","title":"HLF transactivates TFEB to promote gallbladder cancer stem cells' self-renewal and determines tumor response to distinct therapies.","date":"2025","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/40779629","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30628662","id":"PMC_30628662","title":"Eya2 is critical for the E2A‑HLF‑mediated immortalization of mouse hematopoietic stem/progenitor cells.","date":"2019","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30628662","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39864063","id":"PMC_39864063","title":"Protocol for the generation of HLF+ HOXA+ human hematopoietic progenitor cells from pluripotent stem cells.","date":"2025","source":"STAR protocols","url":"https://pubmed.ncbi.nlm.nih.gov/39864063","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40473600","id":"PMC_40473600","title":"SWI/SNF ATPase silenced HLF potentiates lung metastasis in solid cancers.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/40473600","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39872516","id":"PMC_39872516","title":"Construction of an anaplastic thyroid cancer stratification signature to guide immune therapy selection and validation of the pivotal gene HLF through in vitro experiments.","date":"2025","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39872516","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36162014","id":"PMC_36162014","title":"T-Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation for a Patient With Tcf3-Hlf-Positive Acute Lymphoblastic Leukemia Extramedullary Relapse After Unrelated Bone Marrow Transplantation.","date":"2022","source":"Journal of pediatric hematology/oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36162014","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19954622","id":"PMC_19954622","title":"[Severe hypercalcemia complicated in acute lymphoblastic leukemia (ALL) with E2A-HLF fusion gene: report of two cases and literature review].","date":"2009","source":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","url":"https://pubmed.ncbi.nlm.nih.gov/19954622","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15804067","id":"PMC_15804067","title":"[Establishment and characteristics of the human diploid cell strain HLF-02].","date":"2003","source":"Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University","url":"https://pubmed.ncbi.nlm.nih.gov/15804067","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39494255","id":"PMC_39494255","title":"PGV-1 Causes Disarrangement of Spindle Microtubule Organization Resulting in Aberrant Mitosis in HLF and HuH6 Cells Associated with Altered MYCN Status.","date":"2024","source":"Advanced pharmaceutical bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/39494255","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16600109","id":"PMC_16600109","title":"[p38/ERK signal pathways regulating the expression of type I collagen and activity of MMP-2 in TGF-beta1-stimulated HLF-02 cells].","date":"2006","source":"Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases","url":"https://pubmed.ncbi.nlm.nih.gov/16600109","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36553362","id":"PMC_36553362","title":"Peripheral Bone Relapse of Paediatric TCF3-HLF Positive Acute Lymphoblastic Leukaemia during Haematopoietic Stem Cell Transplantation: A Case Report.","date":"2022","source":"Children (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/36553362","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27349115","id":"PMC_27349115","title":"[BLG gene knockout and hLF gene knock-in at BLG locus in goat by TALENs].","date":"2016","source":"Sheng wu gong cheng xue bao = Chinese journal of biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/27349115","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41602466","id":"PMC_41602466","title":"HLF and hTERT cooperatively enable partial immortalization of human hematopoietic stem and progenitor cells.","date":"2026","source":"Frontiers in bioengineering and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/41602466","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41136715","id":"PMC_41136715","title":"Bmi1 represses HLF to drive the formation and development of intrahepatic cholangiocarcinoma.","date":"2025","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/41136715","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39164324","id":"PMC_39164324","title":"Deciphering the role of HLF in idiopathic orbital inflammation: integrative analysis via bioinformatics and machine learning techniques.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/39164324","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40692462","id":"PMC_40692462","title":"[Analysis of 8 children with TCF3:: HLF fusion gene positive acute lymphoblastic leukemia].","date":"2025","source":"Zhonghua er ke za zhi = Chinese journal of pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/40692462","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40827901","id":"PMC_40827901","title":"WTAP Dysregulation Mediates HLF-m6A Modification to Inhibit Trophoblast Ferroptosis in Preeclampsia.","date":"2025","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/40827901","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10353251","id":"PMC_10353251","title":"The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.","date":"1999","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/10353251","citation_count":4200,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11292862","id":"PMC_11292862","title":"HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing.","date":"2001","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/11292862","citation_count":3938,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20965423","id":"PMC_20965423","title":"Hypoxia-inducible factors and the response to hypoxic stress.","date":"2010","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/20965423","citation_count":1898,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10878807","id":"PMC_10878807","title":"Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein.","date":"2000","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/10878807","citation_count":1295,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11823643","id":"PMC_11823643","title":"Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch.","date":"2002","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/11823643","citation_count":1247,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19274049","id":"PMC_19274049","title":"A census of human transcription factors: function, expression and evolution.","date":"2009","source":"Nature reviews. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19274049","citation_count":1191,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20595611","id":"PMC_20595611","title":"Sequencing of 50 human exomes reveals adaptation to high altitude.","date":"2010","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/20595611","citation_count":1179,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14645546","id":"PMC_14645546","title":"Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/14645546","citation_count":1167,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9000051","id":"PMC_9000051","title":"Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells.","date":"1997","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/9000051","citation_count":1082,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19477429","id":"PMC_19477429","title":"Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells.","date":"2009","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/19477429","citation_count":1071,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15247232","id":"PMC_15247232","title":"Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15247232","citation_count":901,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10823831","id":"PMC_10823831","title":"Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10823831","citation_count":891,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27001847","id":"PMC_27001847","title":"Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m⁶A-demethylation of NANOG mRNA.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/27001847","citation_count":889,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9113979","id":"PMC_9113979","title":"A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development.","date":"1997","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9113979","citation_count":847,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29507755","id":"PMC_29507755","title":"VIRMA mediates preferential m6A mRNA methylation in 3'UTR and near stop codon and associates with alternative polyadenylation.","date":"2018","source":"Cell discovery","url":"https://pubmed.ncbi.nlm.nih.gov/29507755","citation_count":829,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15964822","id":"PMC_15964822","title":"Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma.","date":"2005","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15964822","citation_count":803,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18854154","id":"PMC_18854154","title":"Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication.","date":"2008","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/18854154","citation_count":787,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14702039","id":"PMC_14702039","title":"Complete sequencing and characterization of 21,243 full-length human cDNAs.","date":"2003","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14702039","citation_count":754,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"30962421","id":"PMC_30962421","title":"A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30962421","citation_count":732,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9576906","id":"PMC_9576906","title":"The basic-helix-loop-helix-PAS orphan MOP3 forms transcriptionally active complexes with circadian and hypoxia factors.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9576906","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17418410","id":"PMC_17418410","title":"HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity.","date":"2007","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/17418410","citation_count":645,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20534544","id":"PMC_20534544","title":"Natural selection on EPAS1 (HIF2alpha) associated with low hemoglobin concentration in Tibetan highlanders.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20534544","citation_count":619,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17097563","id":"PMC_17097563","title":"Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype.","date":"2006","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/17097563","citation_count":611,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20211142","id":"PMC_20211142","title":"An atlas of combinatorial transcriptional regulation in mouse and man.","date":"2010","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/20211142","citation_count":573,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14691554","id":"PMC_14691554","title":"Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth.","date":"2003","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/14691554","citation_count":515,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19386601","id":"PMC_19386601","title":"Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19386601","citation_count":481,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25043030","id":"PMC_25043030","title":"Fructose-1,6-bisphosphatase opposes renal carcinoma progression.","date":"2014","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/25043030","citation_count":450,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49725,"output_tokens":9994,"usd":0.149542},"stage2":{"model":"claude-opus-4-6","input_tokens":13924,"output_tokens":3586,"usd":0.238905},"total_usd":0.876791,"stage1_batch_id":"msgbatch_01DzrsgVgYngY1hvM3DU1yF2","stage2_batch_id":"msgbatch_01KA9b7iRzKFdhoBUT7vCvSe","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":62192,"output_tokens":14255,"usd":0.200201},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":17884,"output_tokens":4107,"usd":0.288143}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1992,\n      \"finding\": \"HLF encodes a PAR-family bZIP transcription factor that binds DNA as a homodimer or heterodimer with other PAR proteins (DBP, TEF); the t(17;19) translocation fuses the E2A transactivation domain to the HLF bZIP DNA-binding/dimerization domain, creating the E2A-HLF chimeric oncoprotein.\",\n      \"method\": \"Molecular cloning, gel-shift assays, structural analysis of chimeric transcripts\",\n      \"journal\": \"Science; Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — two independent labs simultaneously identified fusion and DNA-binding properties using direct biochemical assays\",\n      \"pmids\": [\"1386162\", \"1516826\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"HLF and E2A-HLF selectively bind the consensus sequence 5'-GTTACGTAAT-3' with high affinity; E2A-HLF chimeras lack an HLF ancillary DNA-binding domain, altering their binding site tolerance and enabling competitive inhibition of wild-type PAR proteins on non-optimal sites.\",\n      \"method\": \"In vitro binding site selection, gel-shift assays, transient transfection reporter assays, mutagenesis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro binding selection combined with mutagenesis and reporter assays in multiple cell types\",\n      \"pmids\": [\"8065331\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The rat HLF gene is transcribed from two alternative promoters producing HLF43 (43 kDa, expressed in brain, liver, kidney) and HLF36 (36 kDa, liver-specific, initiated from a CUG codon); the two isoforms accumulate with different circadian amplitudes and show distinct liver-specific promoter preferences in transfection experiments.\",\n      \"method\": \"Promoter mapping, transfection assays, immunoblot, circadian expression analysis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (promoter mapping, protein characterization, functional transfection) in single rigorous study\",\n      \"pmids\": [\"7556072\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"E2A-HLF-mediated cell transformation requires both the bipartite E2A transactivation domains and the HLF leucine zipper dimerization domain; deletion of either abrogates anchorage-independent growth and tumor formation in nude mice.\",\n      \"method\": \"NIH 3T3 transformation assay, soft agar colony formation, nude mouse tumor assay, domain deletion mutagenesis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — structure-function mutagenesis with multiple in vitro and in vivo oncogenic readouts\",\n      \"pmids\": [\"7760820\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"E2A-HLF reverses both IL-3-deprivation-induced and p53-mediated apoptosis in murine pro-B lymphocytes; expression of a dominant-negative suppressor of E2A-HLF causes rapid apoptosis in t(17;19)+ leukemia cells, indicating the oncoprotein functions primarily as a cell-survival factor.\",\n      \"method\": \"Dominant-negative suppressor expression, IL-3 withdrawal apoptosis assay, p53-mediated apoptosis rescue in pro-B cells\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean loss-of-function and gain-of-function with defined apoptotic phenotypes, replicated with multiple cell models\",\n      \"pmids\": [\"8700228\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"HLF and TEF share an identical DNA consensus binding site (5'-GTTACGTAAT-3') and possess a highly conserved ~40 amino acid transcriptional activation domain (THAD) required for transcriptional activity in both mammalian cells and yeast; deletion of THAD abolishes HLF transcriptional activity.\",\n      \"method\": \"Binding site selection assay, GAL4 fusion reporter assays, deletion mutagenesis in multiple cell types and yeast\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro binding selection plus systematic domain mutagenesis across multiple systems\",\n      \"pmids\": [\"8639829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"E2A-HLF transforms cells as a homodimer acting through direct transcriptional activation of downstream target genes; leucine zipper mutants that prevent heterodimerization with PAR proteins but retain homodimerization still induce anchorage-independent growth, excluding dominant-negative interference as the primary mechanism.\",\n      \"method\": \"Leucine zipper mutagenesis, soft agar transformation assay, NIH 3T3 cells\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mechanistic mutagenesis distinguishing gain-of-function from dominant-negative models with functional readout\",\n      \"pmids\": [\"9032268\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The antiapoptotic activity of E2A-HLF in pro-B cells depends critically on the E2A transactivation domains (AD1 and AD2); the HLF bZIP domain is dispensable for this activity, suggesting E2A-HLF acts as a transcriptional cofactor via protein-protein interactions with the E2A region to alter expression of apoptotic regulators.\",\n      \"method\": \"Domain deletion/mutation panel, IL-3 withdrawal apoptosis assay in FL5.12 pro-B cells, zinc-inducible expression system\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic mutagenesis of both domains with quantitative apoptosis readout\",\n      \"pmids\": [\"9742120\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"HLF (HIF-2alpha/EPAS) forms transcriptionally active heterodimers with Arnt3 (ARNT2); these complexes specifically bind the hypoxia response element (HRE) and activate HRE-driven transcription in Arnt-deficient cells.\",\n      \"method\": \"Yeast two-hybrid, gel mobility shift assay, transfection reporter assay in Arnt-deficient c4 cells\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — two-hybrid identification confirmed by direct DNA-binding assay and functional transcription rescue\",\n      \"pmids\": [\"9704006\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"HLF (HIF-2alpha) possesses two hypoxia-inducible transcriptional activation domains (NAD and CAD); NAD is stabilized post-translationally at hypoxia while CAD is constitutively expressed. CAD interacts with CBP/p300 in both yeast and mammals, and this interaction requires a specific cysteine residue and is potentiated by thioredoxin/Ref-1-mediated redox signaling. Nuclear translocation of thioredoxin is induced by hypoxia.\",\n      \"method\": \"GAL4-fusion transfection assays, mammalian two-hybrid, immunoblot, site-directed mutagenesis of CAD cysteine, thioredoxin nuclear translocation imaging\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal methods including mutagenesis, two-hybrid, and imaging in single comprehensive study\",\n      \"pmids\": [\"10202154\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"E2A-HLF transcriptionally activates SLUG (SNAI2), a zinc finger repressor homologous to C. elegans CES-1; SLUG is nearly as effective as Bcl-2 or Bcl-xL in promoting survival of IL-3-deprived pro-B cells, establishing SLUG as a downstream anti-apoptotic effector of E2A-HLF.\",\n      \"method\": \"Representational difference analysis, reporter assays, pro-B cell survival assay, comparison with Bcl-2/Bcl-xL overexpression\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — target gene identification confirmed with functional survival assay, replicated across multiple constructs\",\n      \"pmids\": [\"10518215\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"HLF directly binds and transactivates the HBV enhancer II region (nt 1640-1663), specifically stimulating pregenome RNA (core promoter) transcription but not pre-core RNA, as demonstrated by yeast one-hybrid screening and transient transfection with HBV expression vectors.\",\n      \"method\": \"Yeast one-hybrid screening, electrophoretic mobility shift assay, transient transfection, primer extension analysis\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct binding confirmed by yeast one-hybrid and EMSA, functional specificity shown by primer extension, single lab\",\n      \"pmids\": [\"10627534\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"HLF and DBP form heterodimers that bind with enhanced affinity to Factor VIII and Factor IX promoters, synergistically transactivating these coagulation factor genes; E2A-HLF also activates these promoters in pre-B ALL cells.\",\n      \"method\": \"Transient transfection reporter assays, electrophoretic mobility shift assay demonstrating heterodimer binding, HepG2 and pre-B ALL cell lines\",\n      \"journal\": \"DNA and cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — EMSA confirms heterodimer mechanism, functional transactivation shown, single lab\",\n      \"pmids\": [\"10073576\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"E2A-HLF transcriptionally activates Groucho-related corepressors (Grg2, Grg6) 10-50 fold; increased Grg1 and Grg4 protein levels also occur. E2A-HLF simultaneously downregulates RUNX1, a transcription factor known to interact with Groucho proteins, suggesting a mechanism linking E2A-HLF to block of differentiation.\",\n      \"method\": \"Representational difference analysis, immunoblot, zinc-inducible E2A-HLF expression in FL5.12 cells, dominant-negative DNA-binding mutant\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — target gene identification by RDA with protein-level confirmation, single lab\",\n      \"pmids\": [\"11486032\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CREB binds the CES-2/E2A-HLF binding element (CBE) and is activated by IL-3 via a PKA-dependent pathway; CREB-mediated activation of a CBE-driven reporter and the bcl-2 promoter (which contains a CRE/CBE site) contributes to IL-3-dependent survival of pro-B cells.\",\n      \"method\": \"EMSA, in vitro translated and bacterially expressed CREB binding to CBE, PKA activation/inhibition, dominant-negative CREB, reporter assay with bcl-2 promoter\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct binding confirmed in vitro, functional pathway validated with pharmacological and genetic tools, single lab\",\n      \"pmids\": [\"11416141\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"HLF (HIF-2alpha) is required for erythropoietin (EPO) gene expression and retinal neovascularization; HLF-knockdown mice fail to upregulate EPO in response to hypoxia-normoxia treatment and do not develop retinopathy of prematurity, while intraperitoneal EPO injection rescues the neovascularization deficit.\",\n      \"method\": \"HLF-knockdown mice (neomycin insertion into exon 1), hyperoxia-normoxia ROP model, angiogenic factor expression profiling, EPO rescue experiment, Cre-mediated HLF restoration\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockdown with specific phenotype, rescue by EPO injection and by Cre-mediated gene restoration, multiple orthogonal validations\",\n      \"pmids\": [\"12606578\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"TEF (PAR bZIP protein closely related to HLF, binding the same DNA consensus) protects pro-B cells from apoptosis upon IL-3 withdrawal but also suppresses expression of the common beta chain of cytokine receptors, causing G0/G1 arrest; E2A-HLF promotes survival more efficiently than TEF but does not downregulate the beta-c chain, delineating distinct functional consequences of bZIP domain target gene differences.\",\n      \"method\": \"Retroviral transduction into FL5.12 cells, IL-3 withdrawal apoptosis assay, flow cytometry cell cycle analysis, immunoblot for beta-c chain\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct functional comparison of HLF-related factor with defined molecular readout, single lab\",\n      \"pmids\": [\"15665112\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PAR bZIP transcription factors DBP, TEF, and HLF collectively control expression of xenobiotic detoxification enzymes (cytochrome P450s, carboxylesterases) and the constitutive androstane receptor (CAR); PAR bZIP triple knockout mice are hypersensitive to xenobiotic compounds.\",\n      \"method\": \"PAR bZIP triple knockout mice, liver and kidney transcriptome comparison, xenobiotic hypersensitivity testing\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic triple knockout with transcriptome and functional phenotype, strong evidence from complete loss-of-function model\",\n      \"pmids\": [\"16814730\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"E2A-HLF transcriptionally upregulates Survivin throughout the cell cycle in t(17;19)+ leukemia cells; Survivin suppresses apoptosis-inducing factor (AIF) translocation from mitochondria to the nucleus. Knockdown of Survivin causes massive caspase-independent apoptosis via AIF translocation, and AIF knockdown confers resistance to this apoptosis.\",\n      \"method\": \"Dominant-negative E2A-HLF suppression, forced E2A-HLF expression in t(17;19)-negative cells, reporter assay, counterflow centrifugal elutriator cell cycle analysis, AIF translocation imaging, AIF knockdown\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — gain and loss of function experiments with mechanistic pathway dissection using AIF knockdown, multiple orthogonal methods\",\n      \"pmids\": [\"19887369\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"E2A-HLF transcriptionally induces LMO2 expression through a PAR binding site in the LMO2 promoter; LMO2 induction is dependent on E2A-HLF's DNA-binding and transactivation activities, and LMO2 knockdown by shRNA induces apoptosis in t(17;19)-ALL cells.\",\n      \"method\": \"Transfection of E2A-HLF into non-t(17;19) ALL cells, PAR-site promoter reporter assay, shRNA knockdown, qPCR expression analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct promoter element identified by reporter assay with mutation, functional knockdown confirms dependency, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"20519628\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"E2A-HLF alone is sufficient to immortalize primary lymphoid progenitors; Lmo2 and Bcl-2 are direct target genes of E2A-HLF, and co-expression of Lmo2 and Bcl-2 phenocopies E2A-HLF immortalization. shRNA knockdown of Lmo2 or pharmacological Bcl-2 inhibition compromises viability of E2A-HLF-immortalized cells.\",\n      \"method\": \"Retroviral transduction, real-time PCR, shRNA knockdown, pharmacological Bcl-2 inhibition, primary hematopoietic cell immortalization assay\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — target gene validation with phenocopy experiment plus independent genetic and pharmacological inhibition\",\n      \"pmids\": [\"21072044\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Meis1 transcriptionally regulates HLF in MLL-AF9 leukemia; Meis1 loss increases oxidative stress and apoptosis in leukemia cells, and HLF overexpression or hypoxia rescues leukemia development in Meis1-deficient cells, placing HLF downstream of Meis1 in a low-oxidative stress maintenance pathway.\",\n      \"method\": \"Inducible Meis1-knockout crossed with MLL-AF9 knockin mice, chromatin immunoprecipitation, gene expression analysis, HLF rescue experiments, oxidative stress measurements\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis established by ChIP and functional rescue in vivo, multiple orthogonal methods\",\n      \"pmids\": [\"25740828\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Hlf is a genetic modifier of voltage-gated sodium channel mutation-induced epilepsy; Hlf knockout exacerbates seizure frequency and reduces survival in Scn2a(Q54) mice, and dietary pyridoxine deficiency phenocopies Hlf deletion, implicating the pyridoxine/GABA pathway as the mechanistic link.\",\n      \"method\": \"Hlf knockout crossed with Scn2a(Q54) epilepsy mouse model, seizure frequency monitoring, survival analysis, pyridoxine-deficient diet intervention\",\n      \"journal\": \"Epilepsy research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis and dietary intervention, but pathway mechanism (pyridoxine) established only by association/diet manipulation, single lab\",\n      \"pmids\": [\"26656780\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"HLF in hepatic stellate cells transcriptionally activates IL-6, which in turn activates STAT3 phosphorylation; STAT3 signaling feeds back to activate HLF expression, forming a feedforward regulatory circuit that drives HSC activation and liver fibrosis. Loss of HLF impairs HSC activation in HLFPB/PB mice.\",\n      \"method\": \"HLF piggyBac knockout mice, primary HSC activation assays, ectopic HLF expression in LX2 cells, IL-6 promoter reporter assays, STAT3 phosphorylation immunoblot, patient fibrotic liver correlation\",\n      \"journal\": \"Gut\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout mouse with primary cell functional validation, feedforward circuit demonstrated by multiple molecular methods and patient data correlation\",\n      \"pmids\": [\"28754776\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"HLF is an oncofetal protein in HCC that transcriptionally activates c-Jun; the HLF/c-Jun axis promotes tumor-initiating cell generation, HCC initiation/progression, and determines sorafenib resistance. HLF expression is reactivated in HCC by SOX2 and OCT4.\",\n      \"method\": \"ChIP, luciferase reporter assay, loss/gain of function in vitro and in vivo, patient-derived xenografts, patient cohort correlation\",\n      \"journal\": \"Gut\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct transactivation shown by ChIP and reporter, functional in vivo validation in PDX, multiple orthogonal methods\",\n      \"pmids\": [\"31118247\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TCF3-HLF recruits HLF binding sites at hematopoietic stem cell/myeloid lineage-associated super-enhancers; it pioneers cooperation with ERG transcription factor and recruits the histone acetyltransferase EP300, conferring vulnerability to EP300 inhibition. Among direct targets, TCF3-HLF activates a MYC enhancer cluster via an HLF binding site.\",\n      \"method\": \"Endogenous TCF3-HLF regulome analysis, functional genomics (CRISPR), ChIP-seq, enhancer mapping, EP300 inhibitor treatment in vivo\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genome-wide regulome plus functional CRISPR screen, direct EP300 recruitment shown, in vivo validation\",\n      \"pmids\": [\"31735627\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Hlf expression specifically marks HSC precursors (pre-HSCs) in the AGM region and fetal liver but not erythro-myeloid progenitors (EMPs) or yolk sac hematopoietic clusters before E9.5; the Evi-1/Hlf axis regulates HSC specification within Hlf+ nascent hematopoietic clusters.\",\n      \"method\": \"Hlf-tdTomato reporter knockin mouse, long-term transplantation assay, in vitro co-culture, lineage tracing\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reporter knockin with functional HSC transplantation readout, genetic epistasis with Evi-1, multiple orthogonal methods\",\n      \"pmids\": [\"31076455\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"E2A-HLF transcriptionally activates Eya2 by binding to its promoter region; Eya2 knockdown in E2A-HLF-immortalized HSPCs reduces colony-forming efficiency, establishing Eya2 as a critical direct downstream effector of E2A-HLF-mediated leukemogenesis.\",\n      \"method\": \"ChIP-qPCR, luciferase reporter assay, Eya2 shRNA knockdown, colony-forming assay\",\n      \"journal\": \"International journal of oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct promoter binding confirmed by ChIP and reporter assay, functional knockdown validates dependency, single lab\",\n      \"pmids\": [\"30628662\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"HLF-expressing cells comprise all stem cell activity in human cord blood during serial transplantation; an HLF genomic reporter strategy selectively labels the most immature human hematopoietic cells, establishing HLF as a defining transcription factor of the human HSC state.\",\n      \"method\": \"Single-cell and population transcriptomics, HLF genomic reporter knockin, ex vivo culture, serial transplantation in vivo\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reporter knockin directly linked to functional transplantation assay, multiple orthogonal validations across multiple tissue sources\",\n      \"pmids\": [\"34499717\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"HLF in triple-negative breast cancer transactivates GGT1 to promote ferroptosis resistance, cell proliferation, metastasis, and cisplatin resistance; HLF expression is induced by TGF-β1 secreted by tumor-associated macrophages, while TNBC cells reciprocally produce IL-6 activating JAK2/STAT3 to induce TGF-β1 in macrophages.\",\n      \"method\": \"Gain/loss-of-function in vitro and in vivo, ChIP and reporter assays for GGT1 transactivation, cytokine neutralization, patient cohort analysis\",\n      \"journal\": \"Journal of hematology & oncology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct transactivation shown by ChIP and reporter assay, feedforward circuit demonstrated by cytokine studies, in vivo validation\",\n      \"pmids\": [\"34991659\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"HLF activation in intrahepatic cholangiocarcinoma is mediated by METTL3-dependent m6A methylation of HLF mRNA; HLF transcriptionally activates FZD4 and FOXQ1, the latter of which activates METTL3 forming a positive feedback loop that drives WNT/β-catenin signaling and tumor stemness.\",\n      \"method\": \"RNA-seq, CUT&Tag chromatin profiling, m6A methylation analysis, loss/gain-of-function experiments, luciferase reporter assay\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — m6A modification writer identified (METTL3), direct HLF target genes identified by CUT&Tag, feedback loop demonstrated mechanistically\",\n      \"pmids\": [\"36958694\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"HLF transcriptionally activates YAP1, modulating the Hippo signaling pathway in ovarian cancer to promote stemness and chemoresistance; miR-520e directly targets HLF 3'-UTR to suppress this axis.\",\n      \"method\": \"Luciferase reporter assay for miR-520e targeting of HLF 3'-UTR, ChIP/reporter for YAP1 transactivation, gain/loss-of-function, patient-derived xenografts\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct transcriptional activation and miRNA targeting confirmed by reporter assays, in vivo PDX validation, single lab\",\n      \"pmids\": [\"37709768\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"miR-103-3p directly targets Hlf 3'-UTR (confirmed by luciferase reporter assay); Hlf overexpression inhibits apoptosis and promotes autophagy in HL-1 cardiomyocytes, reversing the pro-apoptotic, anti-autophagic effects of miR-103-3p in heart failure.\",\n      \"method\": \"Luciferase reporter assay, cell transfection, WB, qPCR in HL-1 cardiomyocyte HF model\",\n      \"journal\": \"ESC heart failure\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — direct miRNA-target interaction confirmed by reporter, functional rescue demonstrated, single lab\",\n      \"pmids\": [\"37562973\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"HLF suppresses lung metastasis in clear cell renal cell carcinoma by regulating LPXN expression, which modulates integration of collagen's mechanical cues with the actin cytoskeleton through Paxillin; HLF is epigenetically silenced at metastatic sites by the SWI/SNF ATPase subunit BRG1.\",\n      \"method\": \"In vivo CRISPR-Cas9 genome-wide screen, HLF KO and overexpression in ccRCC cells, lung metastasis assays, LPXN/Paxillin mechanistic studies, BRG1 inhibitor treatment across cancer types\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — unbiased CRISPR screen, in vivo metastasis assay, mechanistic pathway (BRG1→HLF→LPXN→Paxillin→actin) demonstrated with multiple orthogonal methods\",\n      \"pmids\": [\"40473600\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"HLF transcriptionally activates TFEB and IL-6R in gallbladder cancer; the IL-6/IL-6R/STAT3 axis transactivates HLF forming a positive feedback loop. HLF-driven TFEB activation promotes autophagy and gemcitabine resistance, and induces PD-L1 expression enabling immune evasion in a CD8+ T cell-dependent manner.\",\n      \"method\": \"Loss/gain-of-function experiments, ChIP and reporter assays for TFEB and IL-6R transactivation, patient-derived xenografts, CD8+ T cell depletion experiments\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct transactivation confirmed by ChIP/reporter, in vivo PDX validation, immune mechanism tested with CD8+ T cell depletion, multiple orthogonal methods\",\n      \"pmids\": [\"40779629\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"HLF inhibits PPARα expression in intestinal epithelial cells; intestine-specific Hlf knockout in mice shows that the HLF/PPARα axis modulates gut microbiota-derived extracellular vesicle (fEV) composition containing taurochenodeoxycholic acid (TCDCA), which inhibits hepatocyte ferroptosis and alleviates metabolic-associated fatty liver disease.\",\n      \"method\": \"Intestine-specific Hlf knockout mice, single-cell transcriptomics of cynomolgus monkey intestine, lipidomics of fEVs, hepatocyte ferroptosis assays\",\n      \"journal\": \"iMeta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — tissue-specific knockout with defined molecular mechanism via lipidomics and ferroptosis assay, single study\",\n      \"pmids\": [\"40236774\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"WTAP mediates m6A methylation of HLF mRNA to stabilize it; HLF in turn transcriptionally activates SLC7A11 (system Xc- transporter) to inhibit trophoblast ferroptosis and maintain trophoblast proliferation, migration, and invasion. WTAP downregulation in preeclampsia reduces HLF→SLC7A11 activity, promoting ferroptosis.\",\n      \"method\": \"m6A methylation analysis, mRNA stability assays, ChIP/reporter for SLC7A11 transactivation, trophoblast loss/gain-of-function, ferroptosis assays\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — m6A writer (WTAP) identified, direct transcriptional target (SLC7A11) demonstrated, functional ferroptosis readout, single lab\",\n      \"pmids\": [\"40827901\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Bmi1 represses HLF expression by directly binding to the HLF promoter; HLF functions as a tumor suppressor in intrahepatic cholangiocarcinoma, and HLF knockout promotes ICC development in mouse models, while HLF overexpression inhibits ICC growth in vitro and in vivo.\",\n      \"method\": \"Luciferase reporter assay confirming Bmi1 binds HLF promoter, RNA sequencing, lentiviral HLF overexpression/knockout in human ICC cells, xenograft and primary ICC mouse models\",\n      \"journal\": \"British journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct promoter repression confirmed by reporter assay, in vivo mouse model validation, single lab\",\n      \"pmids\": [\"41136715\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"E4BP4 is a transcriptional target of E2A-HLF; E2A-HLF acts as a transcriptional activator while E4BP4 acts as a transcriptional repressor at the same DNA-recognition sequence, and E4BP4 overexpression (unlike E2A-HLF) does not protect pro-B cells from IL-3 withdrawal-induced apoptosis.\",\n      \"method\": \"Tetracycline-inducible expression system in Baf-3 cells, reporter gene assays, IL-3 withdrawal apoptosis assay\",\n      \"journal\": \"British journal of haematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — inducible expression system with direct reporter assay comparison, functional apoptosis readout, single lab\",\n      \"pmids\": [\"15147370\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"E2A-HLF induces annexin II expression by substituting for cytokine-mediated Ras/PI3K pathway activation; in IL-3-dependent cells, annexin II is regulated by IL-3 via Ras pathways, and E2A-HLF upregulates annexin II in the absence of cytokine.\",\n      \"method\": \"Enforced E2A-HLF expression in IL-3-dependent cells, pathway inhibition studies, comparison with cytokine signaling\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — functional connection established but pathway placement relies on indirect evidence, single lab\",\n      \"pmids\": [\"15070701\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The chimeric E2A-PBX1 and E2A-HLF oncoproteins concentrate in spherical nuclear domains (CODs) distinct from other known nuclear compartments; COD formation requires protein elements from both fusion partners and an intact E2A activation domain, suggesting these domains may concentrate non-DNA-bound protein.\",\n      \"method\": \"Immunofluorescence in transfected cells, co-localization with PML, SC-35, RNA polymerase II, bromouridine nascent transcription, Hoxb7 co-transfection\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — subcellular localization determined by direct immunofluorescence with functional domain requirements mapped, single lab\",\n      \"pmids\": [\"9366523\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TCF3-HLF expression suppresses homologous recombination repair (HRR) activity by decreasing MCPH1 levels, which reduces BRCA1 expression; this HRR deficiency renders TCF3-HLF-positive leukemia cells selectively sensitive to PARP inhibitors (synthetic lethality).\",\n      \"method\": \"HRR activity assay, MCPH1/BRCA1 immunoblot, PARP inhibitor sensitivity assay, in vivo xenograft olaparib treatment\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway (TCF3-HLF→MCPH1→BRCA1→HRR deficiency) established by molecular and functional assays, validated in vivo, single lab\",\n      \"pmids\": [\"27894958\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"HLF is a PAR-family bZIP transcription factor that binds the consensus sequence 5'-GTTACGTAAT-3' as homo- or heterodimers with DBP and TEF to transactivate target genes (EPO, c-Jun, GGT1, LMO2, TFEB, SLC7A11, LPXN, IL-6, YAP1, FZD4, and others) through a conserved ~40 amino acid activation domain that interacts with CBP/p300 in a hypoxia- and redox-regulated manner; in normal biology, HLF functions as a master regulator of hematopoietic stem cell identity, circadian-controlled xenobiotic detoxification, and hypoxia-responsive gene expression (including EPO for retinal vascularization), while the oncogenic t(17;19) E2A-HLF fusion hijacks these transcriptional programs to activate anti-apoptotic targets (SLUG, LMO2, Bcl-2, Survivin, Eya2) and recruit EP300 to stem cell-associated super-enhancers, driving leukemic transformation of pro-B cell progenitors.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll systematically classify each paper before extracting discoveries.\n\n**Classification notes:**\n\n- Papers about HLF as \"Hepatic Leukemia Factor\" (PAR bZIP transcription factor, chromosome 17q22) → KEEP\n- Papers about HLF as \"HIF-1alpha-Like Factor\" / HIF-2alpha / EPAS1 (endothelial PAS domain protein 1, chromosome 2p21) → EXCLUDE (alias collision - different gene)\n- Papers about hLF = human Lactoferrin → EXCLUDE (alias collision)\n- Papers about HLF-1/HLF-02 cell lines (human lung fibroblast lines) → EXCLUDE (cell line name, not gene)\n\n**Key exclusions:**\n- PMID:10202154 - \"HLF\" here = HIF-1alpha-like factor/HIF-2alpha/EPAS1, NOT the PAR bZIP HLF → EXCLUDE\n- PMID:9113979 - Same, HLF = HIF1alpha-like factor = EPAS1 → EXCLUDE\n- PMID:12606578 - HLF/HIF-2alpha knockout → EXCLUDE (EPAS1)\n- PMID:9398602 - HLF/EPAS → EXCLUDE\n- PMID:9704006 - HLF here interacts with Arnt3; context shows HLF = HIF-2alpha/EPAS1 → EXCLUDE\n- All curated papers (Maxwell, Ivan, Ohh, Lando, etc.) about HIF/VHL → EXCLUDE (about HIF pathway, not PAR bZIP HLF)\n- PMID:16707273 - HLF = hepatoma cell line → EXCLUDE\n- PMID:10504033 - HLF = hepatoma cell line → EXCLUDE\n- PMID:28571757 - HLF-1 = human lung fibroblast cell line → EXCLUDE\n- PMID:16600109 - HLF-02 = human lung fibroblast cell line → EXCLUDE\n- PMID:15804067 - HLF-02 cell strain establishment → EXCLUDE\n- PMID:29409862 - hLF(1-11) = lactoferrin peptide → EXCLUDE\n- PMID:36551443 - D-hLF 1-11 = lactoferrin → EXCLUDE\n- PMID:39200089 - hLF(1-11) = lactoferrin → EXCLUDE\n- PMID:19219636 - hLF = human lactoferrin transgenic → EXCLUDE\n- PMID:31661123 - hLF = lactoferrin in goat → EXCLUDE\n- PMID:27349115 - hLF = lactoferrin knock-in → EXCLUDE\n- PMID:25776104 - HLF = hepatoma cell line (HLF cells) → EXCLUDE\n- PMID:39494255 - HLF = hepatoma cell line → EXCLUDE\n- PMID:24284116 - HLF = normal human lung fibroblast cells → EXCLUDE\n- PMID:36374958 - CircCHD2/miR-200b-3p/HLF → KEEP (HLF = hepatic leukemia factor in HSC context)\n- PMID:98 (PMID:39164324) - \"HLF\" = Human lactoferrin in title → EXCLUDE\n\nNow extracting from KEPT papers:\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1992,\n      \"finding\": \"HLF (hepatic leukemia factor) encodes a PAR-subfamily basic leucine zipper (bZIP) transcription factor normally expressed in liver and kidney; the t(17;19) chromosomal translocation fuses the E2A transactivation domain to the HLF bZIP domain, creating the chimeric E2A-HLF oncoprotein in acute B-lineage leukemia.\",\n      \"method\": \"Molecular cloning, Northern blot, chimeric transcript sequencing\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original cloning with direct molecular characterization, replicated by independent lab same year\",\n      \"pmids\": [\"1386162\", \"1516826\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Wild-type HLF binds DNA specifically as a homodimer or heterodimer with other PAR family factors (DBP, TEF); the E2A-HLF fusion protein has markedly impaired homodimerization but retains heterodimeric DNA binding with PAR proteins, suggesting a novel mechanism for leukemogenic conversion.\",\n      \"method\": \"Gel mobility shift assay, in vitro DNA-binding, dimerization assays\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct in vitro binding assays with mutagenesis-level structural dissection\",\n      \"pmids\": [\"1516826\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"HLF and E2A-HLF selectively bind the consensus DNA sequence 5'-GTTACGTAAT-3' with high affinity; E2A-HLF chimeras show reduced tolerance for sequence deviations due to loss of an HLF ancillary DNA-binding domain, and both activate transcription from consensus-site reporter genes in lymphoid and non-lymphoid cells, but E2A-HLF can competitively inhibit wild-type PAR protein activation at suboptimal binding sites.\",\n      \"method\": \"In vitro binding site selection, gel shift assay, transient transfection reporter assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro binding site selection plus functional reporter assays with multiple cell types\",\n      \"pmids\": [\"8065331\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The rat HLF gene is transcribed from two alternative promoters (alpha and beta) producing a 43 kDa protein (HLF43, abundant in brain/liver/kidney) and a novel 36 kDa protein (HLF36, liver-specific, initiated from a CUG codon); the two isoforms accumulate with different circadian amplitudes and have distinct liver-specific promoter preferences in transfection experiments—HLF43 preferentially activates the cholesterol 7α-hydroxylase promoter while HLF36 preferentially activates the albumin promoter.\",\n      \"method\": \"Alternative promoter characterization, CUG-initiation identification, Western blot, transfection reporter assays, circadian expression analysis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods (promoter mapping, translation initiation, functional transactivation assays)\",\n      \"pmids\": [\"7556072\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"E2A-HLF-mediated cell transformation requires both the bipartite E2A transactivation domains and the HLF leucine zipper dimerization domain; mutants lacking either the E2A activation domains or the HLF leucine zipper fail to transform NIH 3T3 cells or support anchorage-independent growth and tumor formation in nude mice.\",\n      \"method\": \"NIH 3T3 transformation assay, soft agar colony formation, nude mouse tumor xenograft, deletion mutagenesis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function mutagenesis with multiple phenotypic readouts including in vivo tumorigenesis\",\n      \"pmids\": [\"7760820\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The E2A-HLF chimeric oncoprotein reverses apoptosis in murine pro-B lymphocytes, blocking both IL-3 withdrawal-induced and p53-mediated cell death; dominant-negative suppression of E2A-HLF in human t(17;19) leukemia cells rapidly induced apoptosis, demonstrating that the oncoprotein promotes cell survival rather than growth.\",\n      \"method\": \"Dominant-negative suppressor expression, IL-3 deprivation apoptosis assay, p53-mediated apoptosis assay in pro-B cells\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean gain- and loss-of-function experiments with defined apoptotic phenotype, published in Nature\",\n      \"pmids\": [\"8700228\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"TEF and HLF share identical DNA-binding consensus sequences (5'-GTTACGTAAT-3') and possess a highly conserved ~40 amino acid transcriptional activation domain (THAD) whose deletion completely abrogates transcriptional activity in both mammalian cells and yeast; this THAD represents one of the most evolutionarily conserved transcriptional activation domains identified.\",\n      \"method\": \"Binding site selection assay, GAL4 fusion deletion mapping, reporter assays in mammalian cells and yeast\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro binding selection plus functional deletion mapping with cross-species validation\",\n      \"pmids\": [\"8639829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"E2A-HLF transforms cells through homodimeric binding to downstream target gene promoters (gain-of-function), not through dominant-negative interference with wild-type PAR proteins; leucine zipper mutants that can homodimerize but cannot heterodimerize with HLF/TEF/DBP retain full transforming activity, and transformation requires intact E2A activator regions.\",\n      \"method\": \"Leucine zipper domain mutagenesis (extended helix, charged residue alterations), NIH 3T3 soft agar transformation assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — structure-function mutagenesis distinguishing homodimer vs. heterodimer mechanisms with functional readout\",\n      \"pmids\": [\"9032268\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"E2A-PBX1 and E2A-HLF chimeric oncoproteins concentrate within discrete spherical nuclear domains (chimeric-E2A oncoprotein domains, CODs) that require protein elements from both fusion partners; wild-type E2A or PBX1 alone show diffuse nuclear distribution, indicating COD formation is a gain-of-function property of the chimera.\",\n      \"method\": \"Immunofluorescence microscopy, nuclear localization analysis, co-transfection experiments\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — localization by immunofluorescence, functional link to transcription suggested but not confirmed\",\n      \"pmids\": [\"9366523\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The antiapoptotic activity of E2A-HLF in IL-3-deprived pro-B cells depends critically on the E2A transactivation domains (AD1 and AD2), not on DNA binding or leucine zipper-mediated dimerization through the HLF bZIP domain; bZIP-disabled mutants retaining either E2A activation domain still extend cell survival, suggesting protein-protein interactions via the E2A N-terminus allow the chimera to act as a transcriptional cofactor.\",\n      \"method\": \"Zinc-inducible expression of E2A-HLF deletion/point mutants in FL5.12 IL-3-dependent pro-B cells, apoptosis assay upon IL-3 withdrawal\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — systematic structure-function analysis with panel of mutants and defined cellular phenotype\",\n      \"pmids\": [\"9742120\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The E2A-HLF chimera abrogates p53-induced apoptosis in myeloid leukemia cells, acting downstream of p53 since p53-responsive genes (p21, Bax) are still normally upregulated; NFIL3, a related bZIP protein binding the same consensus site, cannot substitute for this anti-p53 function, indicating E2A-HLF has unique cell-type-specific survival properties.\",\n      \"method\": \"Temperature-sensitive p53 mutant M1 myeloid cell system, enforced E2A-HLF expression, apoptosis assay, p53-target gene expression analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — epistasis experiment placing E2A-HLF downstream of p53 with defined molecular readouts\",\n      \"pmids\": [\"9694729\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"HLF and E2A-HLF transactivate the HBV enhancer II (EnII) through binding to nucleotides 1640–1663; specifically, HLF activates the core upstream regulatory sequence and predominantly stimulates pregenome RNA synthesis, while FTF activates the full enhancer; E4BP4 binding to the same site has opposing repressive effects.\",\n      \"method\": \"Yeast one-hybrid screening, transient transfection reporter assays, primer extension analysis\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — yeast one-hybrid binding plus functional reporter assays; single lab\",\n      \"pmids\": [\"10627534\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"E2A-HLF activates expression of SLUG, a zinc-finger transcription factor of the Snail family closely related to C. elegans CES-1 antiapoptotic protein; SLUG expression is nearly as effective as Bcl-2 or Bcl-xL in promoting survival of IL-3-deprived pro-B cells, establishing SLUG as a downstream effector of E2A-HLF in blocking apoptosis.\",\n      \"method\": \"E2A-HLF-responsive gene search, SLUG identification, IL-3 withdrawal survival assay with Bcl-2/Bcl-xL comparison\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — gene identification with direct functional validation of downstream effector via survival assay\",\n      \"pmids\": [\"10518215\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"E2A-HLF transgenic mice (lymphoid-directed expression) exhibit T-cell apoptosis, B-cell maturation arrest at an early developmental stage, and susceptibility to infection due to immunodeficiency; several transgenic mice develop T-ALL, demonstrating that E2A-HLF disrupts lymphoid development in vivo and requires additional events for full malignant transformation.\",\n      \"method\": \"Transgenic mouse model (Ig enhancer/promoter-driven E2A-HLF), TUNEL staining, flow cytometry, in vitro colony formation assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo transgenic model with multiple mechanistic readouts\",\n      \"pmids\": [\"10216071\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Two E2A-HLF downstream target genes were identified: ANNEXIN VIII (upregulated in t(17;19)+ leukemia cells) and SRPUL (a novel sushi-repeat protein); both transcripts decline rapidly within 8–12 hours of E2A-HLF suppression, though neither prevents apoptosis in IL-3-deprived pro-B cells, suggesting paraneoplastic rather than core survival roles.\",\n      \"method\": \"Representational difference analysis (RDA) of E2A-HLF-active vs. inactive cells, zinc-inducible dominant-negative system\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — RDA gene identification with inducible system, but downstream functional role not established\",\n      \"pmids\": [\"9864177\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"E2A-HLF activates expression of Groucho-related transcriptional corepressors (Grg2, Grg6, and indirectly Grg1, Grg4) 10–50 fold, and downregulates RUNX1 among known Groucho-interacting transcription factors; a DNA-binding-disabled E2A-HLF mutant still mediates pro-B cell survival and activates Groucho genes, suggesting the survival function operates partly through protein-protein interactions independent of direct DNA binding.\",\n      \"method\": \"Representational difference analysis, zinc-inducible E2A-HLF system in FL5.12 pro-B cells, immunoblot, DNA-binding mutant analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — RDA with inducible system plus mutant dissection establishing pathway position\",\n      \"pmids\": [\"11486032\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CREB is a cellular component of the Ces-2/E2A-HLF binding element (CBE) complex and is part of the IL-3 survival signal; IL-3 stimulation induces CREB phosphorylation at Ser133 partially via PKA; PKA activation prolongs Ba/F3 cell survival in the absence of IL-3; the bcl-2 gene promoter contains functional CRE and CBE sites required for IL-3-inducible expression.\",\n      \"method\": \"EMSA, in vitro translation/recombinant protein binding, PKA inhibitor/activator experiments, luciferase reporter assays with bcl-2 promoter mutations\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods including in vitro binding, pharmacological manipulation, and promoter mutation\",\n      \"pmids\": [\"11416141\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The DBP transcriptional activation domain (TAD) is highly homologous to those of HLF and TEF; deletion of this domain completely abrogates DBP transcriptional activity; the core PAR protein TAD maps to a region of 13 amino acids in HLF (by GAL4-HLF fusion analysis); liver-specific activity is not intrinsic to the TAD but is conferred by other protein regions.\",\n      \"method\": \"GAL4 fusion deletion analysis, transient transfection reporter assays in multiple cell types, comparative sequence analysis\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — systematic deletion mapping in multiple cell contexts; single lab\",\n      \"pmids\": [\"11223263\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"E2A-Hlf expression in bone marrow B-cell progenitors induces short-lived cell clusters without sustained growth; co-expression with Bcl-2 results in sustained self-renewal of pre-B-I cells requiring stromal and IL-7 support, and induces leukemias in irradiated recipients with long latency, demonstrating that E2A-Hlf requires suppression of apoptosis (via Bcl-2) and additional mutations for full leukemogenic conversion.\",\n      \"method\": \"Retroviral transduction-transplantation, bone marrow stromal co-culture, leukemia transplantation assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo and in vitro transformation assay with genetic co-expression dissecting requirements\",\n      \"pmids\": [\"12370314\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Annexin II expression in t(17;19)+ leukemia cells is induced by E2A-HLF and is regulated downstream of Ras/PI3K pathways activated by IL-3; E2A-HLF increases annexin II expression in IL-3-deprived cells, effectively substituting for cytokine-activated Ras signaling.\",\n      \"method\": \"Enforced E2A-HLF expression, cytokine deprivation, Ras pathway inhibitor studies, Western blot\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single lab, pathway placement by pharmacological inhibition without direct binding evidence\",\n      \"pmids\": [\"15070701\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"E4BP4 is a downstream transcriptional target of E2A-HLF in pro-B cells; E2A-HLF acts as a transcriptional activator while E4BP4 acts as a transcriptional repressor at the same DNA binding element (CBE); overexpression of E4BP4 alone cannot block apoptosis from IL-3 withdrawal, distinguishing E2A-HLF's survival function from E4BP4's activity.\",\n      \"method\": \"Tetracycline-inducible expression system in Baf-3 cells, reporter gene assays, IL-3 withdrawal apoptosis assay\",\n      \"journal\": \"British journal of haematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — inducible system with reporter assays and functional apoptosis readout; single lab\",\n      \"pmids\": [\"15147370\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"TEF (thyrotroph embryonic factor), a PAR bZIP protein related to HLF that recognizes the same DNA sequence, protects IL-3-dependent pro-B cells from apoptosis and uniquely downregulates expression of the common beta chain (βc) of cytokine receptors, causing G0/G1 arrest without apoptosis; in contrast, E2A-HLF promotes survival more efficiently but does not downregulate βc, demonstrating distinct functional properties between the two related proteins.\",\n      \"method\": \"Retroviral expression in FL5.12 cells, IL-3 withdrawal survival assay, flow cytometry cell cycle analysis, receptor expression analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — comparative gain-of-function with defined molecular and cellular phenotypes; single lab\",\n      \"pmids\": [\"15665112\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PAR bZIP transcription factors DBP, TEF, and HLF (which accumulate in a circadian manner in liver and kidney) collectively control expression of enzymes and regulators involved in xenobiotic detoxification, including cytochrome P450 enzymes, carboxylesterases, and CAR; triple knockout mice devoid of all three PAR bZIP factors are hypersensitive to xenobiotic compounds.\",\n      \"method\": \"PAR bZIP triple knockout mouse model, liver/kidney transcriptome comparison, xenobiotic sensitivity assays\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic triple-knockout with transcriptome profiling and functional xenobiotic phenotype\",\n      \"pmids\": [\"16814730\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"HLF and DBP form heterodimers that bind to multiple sites in the Factor VIII and Factor IX promoters with enhanced affinity compared to homodimers; HLF alone and in synergistic combination with DBP transactivates the Factor VIII and Factor IX promoters in HepG2 cells; the E2A-HLF chimera can also mediate expression from these promoters in both hepatoma and pre-B ALL cells.\",\n      \"method\": \"Transient transfection reporter assays in HepG2 cells, gel mobility shift assay demonstrating heterodimer binding\",\n      \"journal\": \"DNA and cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — gel shift binding plus reporter assays; single lab\",\n      \"pmids\": [\"10073576\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"E2A-HLF transcriptionally upregulates Survivin expression throughout the cell cycle in t(17;19)+ ALL cells; Survivin suppression induces massive caspase-independent apoptosis involving AIF translocation from mitochondria to nucleus; AIF knockdown confers resistance to Survivin-loss-induced apoptosis, establishing that E2A-HLF promotes cell survival by maintaining Survivin to prevent AIF-mediated mitochondrial apoptosis.\",\n      \"method\": \"Dominant-negative E2A-HLF suppression, enforced E2A-HLF expression, reporter assays, counterflow centrifugal elutriation, dominant-negative Survivin, AIF knockdown, cell cycle analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including gain/loss-of-function, pathway epistasis, and mechanistic validation\",\n      \"pmids\": [\"19887369\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PAR bZIP triple knockout mice (DBP/TEF/HLF-null) develop cardiac hypertrophy and left ventricular dysfunction with low blood pressure, associated with low aldosterone levels and an abnormal cardiovascular response; this demonstrates a role for the PAR bZIP factors including HLF in regulating cardiovascular physiology and aldosterone production.\",\n      \"method\": \"Triple knockout mouse model, cardiac morphology analysis, blood pressure measurement, aldosterone level measurement\",\n      \"journal\": \"American journal of physiology. Regulatory, integrative and comparative physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout with defined cardiovascular phenotype; confounded by triple KO (cannot attribute to HLF alone)\",\n      \"pmids\": [\"20686175\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"E2A-HLF aberrantly induces LMO2 expression through direct binding to a PAR transcription factor binding site in the LMO2 promoter; this induction depends on both the DNA-binding and transactivation activities of E2A-HLF; shRNA-mediated LMO2 silencing in t(17;19)-ALL cells induces apoptosis, establishing LMO2 as a critical E2A-HLF survival target.\",\n      \"method\": \"Transfection of E2A-HLF into non-t(17;19) ALL cells, promoter reporter assays with PAR-site mutations, shRNA knockdown, apoptosis assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — promoter mutagenesis plus gain-of-function and loss-of-function with functional apoptosis readout\",\n      \"pmids\": [\"20519628\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Retroviral expression of E2A-HLF alone is sufficient to immortalize primary lymphoid progenitors; Lmo2 and Bcl-2 are identified as direct downstream target genes of E2A-HLF; co-expression of Lmo2 and Bcl-2 alone recapitulates E2A-HLF immortalization; shRNA knockdown of Lmo2 or pharmacological BCL-2 inhibition in E2A-HLF-immortalized cells severely compromises viability.\",\n      \"method\": \"Retroviral expression, real-time PCR in patient biopsies and cell lines, shRNA knockdown, BCL-2 pharmacological inhibition\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal approaches (genetic and pharmacological) with patient sample validation\",\n      \"pmids\": [\"21072044\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Zfp521/ZNF521 was identified as a cooperative gene required with E2A-HLF to develop acute B-lineage leukemia; retroviral insertional mutagenesis in E2A-HLF knock-in mice identified Gfi1, Ikaros, and Zfp521 as common integration sites; tumors with Zfp521 integration exclusively showed B-lineage ALL phenotype; ZNF521 is overexpressed in human t(17;19)-positive leukemic cell lines.\",\n      \"method\": \"Inducible knock-in mice, retroviral insertional mutagenesis, inverse PCR, ZNF521 expression analysis in human cell lines, double transgenic mice\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic screen with independent validation in human cells and double-transgenic mouse model\",\n      \"pmids\": [\"20062079\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"E2A-HLF transcriptionally upregulates death receptors DR4 and DR5 through direct binding to the 5' upstream region of the DR4 gene in a DNA-binding and transactivation-dependent manner; this sensitizes t(17;19)-ALL cells to TRAIL-mediated apoptosis via the extrinsic pathway, providing a potential basis for graft-versus-leukemia effects.\",\n      \"method\": \"Reporter assays with DR4 promoter regions, enforced E2A-HLF expression in non-t(17;19) cells, recombinant TRAIL apoptosis assay\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — promoter reporter plus gain-of-function with functional TRAIL sensitivity readout; single lab\",\n      \"pmids\": [\"22743623\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"MEIS1 regulates HLF expression in MLL-fusion leukemia (ChIP-seq/gene expression analysis); Meis1 loss leads to increased oxidative stress and apoptosis in leukemic cells; exogenous HLF expression rescues leukemia development in Meis1-deficient cells by reversing the oxidative stress phenotype, placing HLF downstream of MEIS1 in a pathway controlling reactive oxygen species and leukemia maintenance.\",\n      \"method\": \"Inducible Meis1-knockout mice crossed with MLL-AF9 knock-in, ChIP, gene expression profiling, HLF rescue experiment, oxidative stress measurement\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-confirmed target plus genetic epistasis rescue experiment in vivo\",\n      \"pmids\": [\"25740828\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Hlf is a genetic modifier of epilepsy caused by voltage-gated sodium channel mutations; Hlf knockout mice crossed with Scn2a(Q54) epilepsy mice show elevated seizure frequency and reduced survival; dietary pyridoxine deficiency similarly elevates seizures, and Hlf heterozygous knockout worsens survival in Scn1a(KO/+) Dravet syndrome mice, suggesting HLF modifies epilepsy severity through the pyridoxine metabolic pathway.\",\n      \"method\": \"Hlf targeted knockout mouse model, double mutant crosses with Scn2a(Q54) and Scn1a(KO/+), seizure frequency monitoring, pyridoxine-deficient diet experiment\",\n      \"journal\": \"Epilepsy research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic modifier analysis with defined phenotype; mechanistic link to pyridoxine pathway is indirect\",\n      \"pmids\": [\"26656780\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TCF3-HLF expression suppresses homologous recombination repair (HRR) activity by decreasing MCPH1 levels, which in turn reduces BRCA1 expression; this HRR deficiency causes synthetic lethality with PARP inhibitors, and olaparib was effective in an in vivo xenograft model of TCF3-HLF-positive leukemia.\",\n      \"method\": \"HRR activity assay, MCPH1/BRCA1 expression analysis, PARP inhibitor cytotoxicity screening, in vivo xenograft\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway (TCF3-HLF → MCPH1 → BRCA1 → HRR) supported by expression and functional assays\",\n      \"pmids\": [\"27894958\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"HLF directly binds to the BS1 site of the miR-132 promoter to enhance miR-132 expression in glioma cells; HLF-mediated miR-132 directly targets and suppresses TTK kinase expression; TTK overexpression reverses the inhibitory effects of miR-132 or HLF on cancer cell proliferation, metastasis, and radioresistance, establishing an HLF→miR-132→TTK axis.\",\n      \"method\": \"Luciferase reporter assay (miR-132 promoter with BS1 site), lentiviral transduction, wound healing, transwell invasion, clonogenic assay, TTK rescue experiments\",\n      \"journal\": \"Biomedicine & pharmacotherapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — reporter assay for direct binding plus functional epistasis rescue; single lab\",\n      \"pmids\": [\"27522003\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"HLF expression is confined to activated hepatic stellate cells (HSCs) in fibrotic liver; HLF transcriptionally enhances IL-6 expression and intensifies STAT3 phosphorylation to promote HSC activation; conversely, IL-6/STAT3 signaling activates HLF expression, completing a feedforward regulatory circuit; HLF loss impairs primary HSC activation and attenuates liver fibrosis in HLF-knockout mice.\",\n      \"method\": \"HLF knockout (HLF-PB/PB) mouse model, primary murine HSC isolation and culture, LX2 human HSC line, ectopic HLF expression, IL-6 and p-STAT3 measurement, patient fibrotic liver correlation\",\n      \"journal\": \"Gut\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo knockout plus in vitro gain/loss-of-function with defined molecular mechanism (feedforward circuit)\",\n      \"pmids\": [\"28754776\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"HLF is an oncofetal protein reactivated in HCC by SOX2 and OCT4; HLF transcriptionally activates c-Jun to promote tumor initiating cell (TIC) generation and TIC-like properties in hepatoma cells; the HLF/c-Jun axis determines sorafenib response, and HLF interference abrogates c-Jun activation and enhances sorafenib sensitivity in patient-derived xenografts.\",\n      \"method\": \"ChIP/reporter assays for HLF→c-Jun transactivation, in vivo tumor models, patient cohort analysis, PDX sorafenib response\",\n      \"journal\": \"Gut\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct transactivation evidence plus in vivo gain/loss-of-function and PDX validation\",\n      \"pmids\": [\"31118247\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TCF3-HLF recruits HLF binding sites at hematopoietic stem cell/myeloid lineage-associated super-enhancers to drive lineage identity and self-renewal; TCF3-HLF directly activates MYC through hijacking an HLF binding site in a MYC enhancer cluster; TCF3-HLF pioneers cooperation with ERG and recruits histone acetyltransferase EP300, conferring susceptibility to EP300 inhibition.\",\n      \"method\": \"ChIP-seq of endogenous TCF3-HLF, functional genomics, CRISPRi, EP300 inhibitor treatment, in vivo leukemia propagation assays\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — genome-wide ChIP-seq with functional CRISPR validation and in vivo confirmation\",\n      \"pmids\": [\"31735627\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Eya2 is a direct transcriptional target of E2A-HLF, identified by ChIP-qPCR and reporter assay showing E2A-HLF binds the Eya2 promoter consensus sequence; Eya2 is highly expressed in E2A-HLF-immortalized mouse HSPCs; Eya2 knockdown in E2A-HLF-immortalized cells reduces colony-forming efficiency, demonstrating Eya2 is required for E2A-HLF-mediated self-renewal.\",\n      \"method\": \"ChIP-qPCR, luciferase reporter assay, shRNA knockdown, colony formation assay\",\n      \"journal\": \"International journal of oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus reporter assay plus functional knockdown; single lab\",\n      \"pmids\": [\"30628662\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Hlf expression specifically marks a developmental continuum from HSC precursors to HSCs but not erythro-myeloid progenitors; in the Hlf-tdTomato reporter mouse, Hlf is expressed in intra-aortic hematopoietic clusters and fetal liver HSCs but not in EMPs; HSC specification is regulated by an Evi-1/Hlf axis, active only within Hlf+ nascent hematopoietic clusters.\",\n      \"method\": \"Hlf-tdTomato knock-in reporter mouse, in vitro co-culture, long-term transplantation assay, Evi-1/Hlf axis characterization\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reporter mouse with transplantation assay and genetic axis characterization\",\n      \"pmids\": [\"31076455\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"HLF downregulation promotes NSCLC metastasis by activating NF-κB/p65 signaling through disrupting nuclear translocation of PPARα and PPARγ, thereby promoting anaerobic metabolism to support anchorage-independent growth under low nutritional conditions; both genetic deletion and methylation contribute to HLF downregulation in NSCLC.\",\n      \"method\": \"In vivo lung colonization/metastasis models, HLF overexpression/silencing, NF-κB/PPAR localization assays, metabolic assays\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — in vivo metastasis model with mechanistic pathway characterization; single lab\",\n      \"pmids\": [\"32289442\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"miR-98 suppresses hepatic stellate cell activation by directly targeting the 3'UTR of HLF mRNA (confirmed by luciferase reporter assay); HLF overexpression increases HSC activation by inducing HIF-1α expression and activating TGF-β/Smad2/3 signaling; in vivo ago-miR-98 injection attenuates liver fibrosis in multiple murine models and suppresses HLF expression.\",\n      \"method\": \"Luciferase 3'UTR reporter assay, HLF overexpression, HIF-1α induction, TGF-β/Smad2/3 pathway analysis, in vivo fibrosis models\",\n      \"journal\": \"Frontiers in cell and developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct 3'UTR binding validated plus pathway characterization in multiple in vivo fibrosis models\",\n      \"pmids\": [\"32637414\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"HLF is one of the most specific transcriptional markers of human HSCs; HLF-expressing cells comprise all stem cell activity in culture and during serial transplantation; a genomic HLF reporter strategy selectively labels the most immature blood cells and tracks all hematopoietic stem cell activity, establishing HLF as a defining transcription factor of the human HSC state.\",\n      \"method\": \"Single-cell and population transcriptomics, genomic HLF reporter (knock-in), serial transplantation assay in vivo\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reporter mouse with serial transplantation functionally establishing HSC identity\",\n      \"pmids\": [\"34499717\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Hlf-labeled early cells (marked by Hlf-CreER at E9.5) contribute to and retain the HSC pool in adult bone marrow with long-term balanced multilineage hematopoiesis; CD45+ pre-HSCs at E10.5 exist exclusively in the Hlf-tdTomato-positive population, indicating Hlf expression is gained prior to or concurrently with CD45 during HSC specification.\",\n      \"method\": \"Hlf-tdTomato knock-in reporter, Hlf-CreER lineage tracing (single-dose induction at E9.5), long-term transplantation\",\n      \"journal\": \"Frontiers in cell and developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — lineage tracing with functional HSC transplantation assay\",\n      \"pmids\": [\"34589491\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"HLF is regulated by TGF-β1 secreted by tumor-associated macrophages; HLF transactivates GGT1 (gamma-glutamyltransferase 1) to promote ferroptosis resistance, driving TNBC cell proliferation, metastasis, and cisplatin resistance; reciprocally, IL-6 from TNBC cells activates JAK2/STAT3 in macrophages to induce TGF-β1 secretion, constituting a feed-forward IL-6–TGF-β1 circuit sustaining HLF activation.\",\n      \"method\": \"ChIP/reporter assays for HLF→GGT1 transactivation, ferroptosis assays, TNBC xenograft models, cytokine pathway inhibition\",\n      \"journal\": \"Journal of hematology & oncology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-confirmed transactivation plus in vivo xenograft with defined pathway circuit\",\n      \"pmids\": [\"34991659\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CircCHD2 functions as a miR-200b-3p sponge, thereby relieving miR-200b-3p-mediated repression of HLF in hepatic stellate cells; enforced HLF expression reverses the suppressive effects of miR-200b-3p overexpression on HSC proliferation and activation markers (α-SMA, Col1A1), placing HLF downstream of the circCHD2/miR-200b-3p axis in liver cirrhosis progression.\",\n      \"method\": \"Luciferase reporter assay (circCHD2/miR-200b-3p/HLF interactions), TGF-β1-stimulated LX-2 cell model, siRNA knockdown, qPCR/Western blot\",\n      \"journal\": \"Journal of environmental pathology, toxicology and oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — luciferase reporter plus rescue experiments; single lab, cell line only\",\n      \"pmids\": [\"36374958\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"HLF activation in intrahepatic cholangiocarcinoma (ICC) is mediated by METTL3-dependent m6A methylation of HLF mRNA; HLF transcriptionally activates FZD4 and FOXQ1; FOXQ1 in turn transcriptionally activates METTL3, forming a positive feedback loop that activates WNT/β-catenin signaling and tumor stemness.\",\n      \"method\": \"RNA-seq, CUT&Tag (HLF chromatin binding), m6A methylation assay, loss/gain-of-function experiments, METTL3/HLF reporter circuit validation\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — CUT&Tag for direct binding plus m6A mechanistic validation and feedback loop characterization\",\n      \"pmids\": [\"36958694\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"miR-103-3p targets HLF mRNA (validated by luciferase reporter assay); miR-103-3p overexpression promotes apoptosis and inhibits autophagy in HL-1 cardiomyocytes; HLF overexpression reverses this phenotype, inhibiting apoptosis and promoting autophagy, establishing an miR-103-3p/HLF axis regulating cardiomyocyte survival.\",\n      \"method\": \"Luciferase reporter assay, HL-1 cell transfection, apoptosis assay, autophagy measurement\",\n      \"journal\": \"ESC heart failure\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — luciferase reporter validation plus gain/loss-of-function with defined cellular phenotypes; single lab\",\n      \"pmids\": [\"37562973\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"HLF transcriptionally activates YAP1 expression in ovarian cancer cells; miR-520e directly targets the HLF 3'UTR (validated by reporter assay); the miR-520e/HLF/YAP1 axis modulates Hippo signaling to regulate ovarian cancer stemness, proliferation, metastasis, and carboplatin resistance.\",\n      \"method\": \"miR-520e 3'UTR reporter assay, HLF loss/gain-of-function, YAP1 reporter/expression analysis, PDX carboplatin response\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — reporter assay plus PDX validation; single lab\",\n      \"pmids\": [\"37709768\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"HLF expression is epigenetically silenced in metastatic ccRCC by the SWI/SNF ATPase subunit BRG1; HLF suppresses lung metastasis by regulating LPXN (leupaxin) expression, which modulates integration of collagen mechanical cues with the actin cytoskeleton through Paxillin; BRG1 inhibition restores HLF expression and reduces cell invasion across multiple cancer types.\",\n      \"method\": \"In vivo CRISPR-Cas9 genome-wide screen, HLF overexpression/depletion in ccRCC migration/metastasis assays, BRG1 ChIP/epigenetic silencing analysis, LPXN/Paxillin pathway characterization\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vivo CRISPR screen plus mechanistic pathway characterization with epigenetic regulation\",\n      \"pmids\": [\"40473600\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"HLF efficiently marks HSC-fated artery endothelial cells during a narrow developmental window; guided by arterial HSC origins, hPSC differentiation through artery endothelium rapidly generates >90% pure HLF+HOXA+ hematopoietic progenitors within 10 days that express hallmark HSC transcription factors and generate multiple blood lineages.\",\n      \"method\": \"Non-invasive genetic lineage tracing in mouse embryos, hPSC stepwise differentiation protocol with defined media, single-cell profiling, in vitro multilineage differentiation\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo lineage tracing plus functional hPSC differentiation with HLF as HSC identity marker\",\n      \"pmids\": [\"38569552\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"HLF transcriptionally activates TFEB and IL-6R as direct target genes in gallbladder cancer stem cells; the IL-6/IL-6R/STAT3 axis transactivates HLF forming a positive feedback loop; HLF promotes cancer stem cell expansion and gemcitabine resistance via TFEB-induced autophagy; HLF also drives TFEB-induced PD-L1 expression to govern CD8+ T cell-dependent immune evasion.\",\n      \"method\": \"ChIP/CUT&Tag for HLF→TFEB/IL-6R binding, luciferase reporter assays, in vivo xenograft/PDX models, CD8+ T cell depletion experiments\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — CUT&Tag direct binding evidence with in vivo validation of multiple downstream mechanisms\",\n      \"pmids\": [\"40779629\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Bmi1 represses HLF by directly binding to its promoter (validated by luciferase reporter assay) in intrahepatic cholangiocarcinoma; HLF overexpression inhibits ICC growth in vitro and in vivo; HLF repression reverses the inhibitory effects of Bmi1 knockdown on cell survival and proliferation, establishing HLF as a tumor suppressor downstream of Bmi1 in ICC.\",\n      \"method\": \"RNA-seq, luciferase reporter assay (Bmi1 binding to HLF promoter), lentiviral overexpression/knockout, xenograft and primary ICC mouse models\",\n      \"journal\": \"British journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reporter assay for direct binding plus in vivo functional validation; single lab\",\n      \"pmids\": [\"41136715\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"HLF transcriptionally activates SLC7A11 to inhibit trophoblast ferroptosis; WTAP-dependent m6A methylation stabilizes HLF mRNA; WTAP downregulation in preeclampsia reduces HLF levels, leading to reduced SLC7A11 expression and increased ferroptosis in trophoblasts, impairing their proliferation, migration, and invasion.\",\n      \"method\": \"Reporter assays for HLF→SLC7A11 transactivation, m6A methylation analysis, WTAP knockdown, ferroptosis assays, trophoblast functional assays\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — transactivation reporter plus m6A mechanistic link; single lab\",\n      \"pmids\": [\"40827901\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"HLF and hTERT co-overexpression in human HSPCs enables partial immortalization (up to 70 days in culture) with limited differentiation capacity; HLF alone (as a stem cell maintenance regulator) is insufficient without hTERT-mediated telomere maintenance, and the combination maintains HSPC identity markers.\",\n      \"method\": \"Lentiviral co-overexpression, BaEV-mediated transduction, long-term culture, lineage differentiation assays\",\n      \"journal\": \"Frontiers in bioengineering and biotechnology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — functional co-expression experiment; single lab, partial immortalization only\",\n      \"pmids\": [\"41602466\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"HLF (hepatic leukemia factor) is a PAR-subfamily bZIP transcription factor that binds the consensus sequence 5'-GTTACGTAAT-3' as a homodimer or heterodimer with DBP/TEF, activates target genes through a conserved ~13–40 amino acid transactivation domain (THAD), and functions in circadian-regulated xenobiotic detoxification, HSC identity/self-renewal (operating downstream of MEIS1 and in an Evi-1/HLF axis), and tissue-specific gene regulation (Factor VIII/IX, HBV enhancer II, cholesterol 7α-hydroxylase, albumin); in the oncogenic E2A-HLF fusion arising from t(17;19) translocation, the E2A transactivation domains drive leukemogenesis by activating survival genes (SLUG, LMO2, Survivin, Groucho-related corepressors, Eya2) and blocking apoptosis downstream of p53 through homodimeric DNA binding, while in non-leukemic contexts HLF suppresses metastasis via LPXN/Paxillin-mediated cytoskeletal regulation (epigenetically silenced by BRG1), promotes liver fibrosis through a HLF/IL-6/STAT3 feedforward circuit in hepatic stellate cells, and drives cancer progression by transactivating c-Jun, GGT1, YAP1, FZD4, TFEB, and IL-6R depending on cellular context.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"HLF is a PAR-family basic leucine zipper (bZIP) transcription factor that binds the consensus sequence 5'-GTTACGTAAT-3' as homodimers or heterodimers with DBP and TEF, utilizing a conserved ~40 amino acid activation domain (THAD) essential for transcriptional activity [PMID:1386162, PMID:8065331, PMID:8639829]. HLF is a defining transcription factor of the hematopoietic stem cell state—marking all serial-transplantation stem cell activity in human cord blood and specifying HSC precursors during embryonic hematopoiesis—and collectively with DBP and TEF controls circadian xenobiotic detoxification gene expression [PMID:34499717, PMID:31076455, PMID:16814730]. In non-hematopoietic contexts, HLF transactivates diverse target genes including c-Jun, GGT1, IL-6, SLC7A11, TFEB, YAP1, LPXN, and FZD4, participating in feedforward circuits with IL-6/STAT3 signaling to regulate hepatic stellate cell activation, ferroptosis resistance, and tumor stemness [PMID:28754776, PMID:34991659, PMID:31118247, PMID:36958694, PMID:40473600]. The t(17;19)(q22;p13) translocation fuses E2A transactivation domains to the HLF bZIP domain, creating the E2A-HLF oncoprotein that drives pro-B cell acute lymphoblastic leukemia by transcriptionally activating anti-apoptotic targets (SLUG, LMO2, Bcl-2, Survivin, Eya2) and recruiting EP300 to hematopoietic stem cell-associated super-enhancers [PMID:8700228, PMID:10518215, PMID:21072044, PMID:31735627].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"Identification of HLF as a PAR-family bZIP transcription factor and discovery of the t(17;19) E2A-HLF fusion established the gene's dual identity as a normal transcription factor and an oncogenic partner in pro-B ALL.\",\n      \"evidence\": \"Molecular cloning of chimeric transcripts from t(17;19)+ leukemia, gel-shift assays demonstrating DNA binding and dimerization, by two independent laboratories\",\n      \"pmids\": [\"1386162\", \"1516826\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous HLF target genes in normal cells unknown\", \"Mechanism of leukemogenesis not established\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Characterization of HLF isoforms and domain requirements for transformation revealed that HLF is expressed from alternative promoters with circadian variation and that E2A-HLF oncogenicity requires both the E2A transactivation and HLF dimerization domains.\",\n      \"evidence\": \"Promoter mapping and circadian expression analysis in rat tissues; NIH 3T3 transformation assay with domain deletions and nude mouse tumor formation\",\n      \"pmids\": [\"7556072\", \"7760820\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream targets of E2A-HLF not identified\", \"Role of individual HLF isoforms in vivo unclear\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Demonstrating that E2A-HLF functions primarily as an anti-apoptotic factor in pro-B cells, and that HLF/TEF share a conserved activation domain (THAD), defined the core survival mechanism of E2A-HLF leukemogenesis and the functional architecture of PAR bZIP proteins.\",\n      \"evidence\": \"Dominant-negative E2A-HLF triggers apoptosis in t(17;19)+ cells; IL-3 withdrawal and p53-mediated apoptosis rescue; THAD deletion abolishes transactivation in yeast and mammalian cells\",\n      \"pmids\": [\"8700228\", \"8639829\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct anti-apoptotic target genes not yet identified\", \"Whether THAD mediates cofactor recruitment unknown\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Leucine zipper mutagenesis demonstrated that E2A-HLF transforms as a gain-of-function homodimer rather than through dominant-negative interference with endogenous PAR proteins, resolving the primary oncogenic mechanism.\",\n      \"evidence\": \"Leucine zipper mutants preventing PAR heterodimerization but retaining homodimerization still induce soft agar colony growth in NIH 3T3 cells\",\n      \"pmids\": [\"9032268\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Target genes of the homodimer not identified\", \"Role of E2A-HLF nuclear localization domains not addressed\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Identification of SLUG as a direct E2A-HLF target gene that phenocopies Bcl-2-mediated survival provided the first mechanistic link between E2A-HLF transcriptional output and the anti-apoptotic program; simultaneously, HLF's CAD was shown to recruit CBP/p300 in a redox-regulated manner.\",\n      \"evidence\": \"Representational difference analysis identified SLUG; SLUG overexpression rescues IL-3 withdrawal apoptosis; GAL4 fusions and mammalian two-hybrid mapped CAD-CBP/p300 interaction requiring a redox-sensitive cysteine\",\n      \"pmids\": [\"10518215\", \"10202154\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether HLF (not E2A-HLF) also activates SLUG in normal cells unknown\", \"In vivo role of redox regulation of HLF-CBP interaction not tested\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"HLF knockout mice revealed the physiological requirement for HLF in hypoxia-induced EPO expression and retinal neovascularization, establishing HLF's role in oxygen-sensing physiology beyond hematopoiesis.\",\n      \"evidence\": \"HLF-knockdown mice (neomycin insertion) fail to upregulate EPO and lack retinopathy of prematurity; intraperitoneal EPO rescues neovascularization\",\n      \"pmids\": [\"12606578\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Note: this finding refers to HIF-2α/EPAS1 and may reflect nomenclature overlap rather than the PAR bZIP HLF gene\", \"Tissue-specific contributions of HLF vs other HIF family members to EPO regulation not resolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"The PAR bZIP triple knockout (Dbp/Tef/Hlf) revealed that HLF collaborates with its paralogs to control xenobiotic detoxification gene expression, defining the collective circadian detoxification function of the PAR bZIP family.\",\n      \"evidence\": \"Triple KO mice show transcriptomic loss of cytochrome P450s, carboxylesterases, and CAR expression; hypersensitivity to xenobiotic compounds\",\n      \"pmids\": [\"16814730\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Individual contribution of HLF versus DBP and TEF not delineated\", \"Whether circadian oscillation of HLF directly drives rhythmic drug metabolism not established\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identification of LMO2 and Bcl-2 as direct E2A-HLF targets whose co-expression phenocopies E2A-HLF-mediated immortalization established the minimal downstream program sufficient for leukemic transformation.\",\n      \"evidence\": \"ChIP and PAR-site reporter assays for LMO2; LMO2 knockdown and Bcl-2 pharmacological inhibition compromise E2A-HLF-immortalized cell viability; LMO2+Bcl-2 co-expression phenocopies immortalization\",\n      \"pmids\": [\"20519628\", \"21072044\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether additional targets are required for full leukemogenesis in vivo\", \"Mechanism by which LMO2 cooperates with Bcl-2 at the molecular level unclear\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Positioning HLF downstream of Meis1 in MLL-AF9 leukemia as a mediator of low-oxidative-stress maintenance revealed HLF's role in protecting leukemia stem cells from oxidative damage.\",\n      \"evidence\": \"Meis1 knockout increases oxidative stress; ChIP confirms Meis1 binding at HLF; HLF overexpression rescues leukemia development in Meis1-deficient cells\",\n      \"pmids\": [\"25740828\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct oxidative-stress target genes of HLF not identified\", \"Whether this axis operates in normal HSCs not tested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Convergent evidence from reporter knockin mice, human cord blood transplantation, and regulome mapping established HLF as a master identity gene of hematopoietic stem cells and revealed that TCF3-HLF (E2A-HLF) hijacks HSC-associated super-enhancers by recruiting EP300.\",\n      \"evidence\": \"Hlf-tdTomato reporter marks pre-HSCs in AGM/fetal liver; HLF-reporter labels all serial-transplantation activity in human cord blood; ChIP-seq/CRISPR in TCF3-HLF+ cells identifies EP300-occupied super-enhancers\",\n      \"pmids\": [\"31076455\", \"34499717\", \"31735627\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How HLF expression is extinguished during HSC differentiation remains unclear\", \"Whether EP300 recruitment is direct or mediated through additional cofactors not resolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Discovery of HLF-mediated transactivation of GGT1 in TNBC and feedforward circuits with tumor-associated macrophage-derived TGF-β1 expanded HLF's role to ferroptosis resistance and tumor-immune crosstalk in solid cancers.\",\n      \"evidence\": \"ChIP/reporter assays for GGT1; cytokine neutralization disrupts TGF-β1/HLF/IL-6 feedforward loop; in vivo TNBC metastasis/cisplatin resistance models\",\n      \"pmids\": [\"34991659\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether HLF regulates ferroptosis through additional targets beyond GGT1\", \"Generalizability of the macrophage-HLF feedforward circuit across cancer types not tested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Genome-wide CRISPR screening and multi-cancer functional studies revealed HLF as a metastasis suppressor (via LPXN/Paxillin/actin regulation) epigenetically silenced by BRG1, and as a context-dependent transcriptional activator of TFEB, SLC7A11, and PPARα governing autophagy, ferroptosis, and metabolic liver disease.\",\n      \"evidence\": \"In vivo CRISPR screen in ccRCC; intestine-specific Hlf KO modulates gut microbiota-derived EVs; ChIP/reporter for TFEB, SLC7A11, LPXN in multiple cancer and disease models\",\n      \"pmids\": [\"40473600\", \"40236774\", \"40827901\", \"40779629\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for HLF target gene selectivity across tissues not determined\", \"Whether BRG1-mediated epigenetic silencing of HLF is reversible therapeutically in metastatic settings\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The mechanism by which HLF selects different target gene programs across tissues (HSCs vs. hepatocytes vs. epithelia) and whether its circadian oscillation directly controls the timing of these tissue-specific functions remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model of HLF-DNA or HLF-cofactor complexes\", \"Tissue-specific cofactor requirements for HLF target selectivity not determined\", \"In vivo single-gene HLF knockout phenotype in adult hematopoiesis not fully characterized\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 1, 5]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 5, 10, 19, 23, 24, 29, 30, 34, 36]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [9, 40]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0074160\", \"supporting_discovery_ids\": [5, 10, 19, 24, 29, 30, 34, 36]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [26, 28]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [4, 10, 18, 20]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 6, 25, 41]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [32, 34]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"DBP\",\n      \"TEF\",\n      \"EP300\",\n      \"STAT3\",\n      \"ERG\",\n      \"MEIS1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"HLF is a PAR-subfamily basic leucine zipper (bZIP) transcription factor that binds the consensus sequence 5'-GTTACGTAAT-3' as a homodimer or heterodimer with DBP and TEF, activating target genes through a highly conserved transactivation domain (THAD) in liver, kidney, brain, and hematopoietic stem cells [PMID:1386162, PMID:8065331, PMID:7556072, PMID:8639829]. In normal physiology, HLF marks and maintains hematopoietic stem cell identity from embryonic specification onward, operates downstream of MEIS1 and within an Evi-1/HLF axis to control HSC self-renewal and oxidative stress resistance, and cooperates with DBP and TEF to drive circadian xenobiotic detoxification in liver and kidney [PMID:34499717, PMID:31076455, PMID:25740828, PMID:16814730]. In disease contexts, HLF promotes hepatic stellate cell activation and liver fibrosis through an HLF/IL-6/STAT3 feedforward circuit, transactivates diverse oncogenic targets (c-Jun, GGT1, YAP1, FZD4, TFEB, IL-6R) in solid tumors, and suppresses metastasis in ccRCC via LPXN/Paxillin-mediated cytoskeletal regulation when not epigenetically silenced by BRG1 [PMID:28754776, PMID:31118247, PMID:34991659, PMID:40473600, PMID:40779629]. The t(17;19) chromosomal translocation fuses E2A transactivation domains to the HLF bZIP domain, creating the E2A-HLF oncoprotein that drives B-lineage acute lymphoblastic leukemia by blocking apoptosis downstream of p53 and activating survival targets including SLUG, LMO2, Survivin, and MYC through hijacking of HLF-bound enhancers [PMID:1386162, PMID:8700228, PMID:10518215, PMID:20519628, PMID:31735627].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"Cloning of HLF revealed it as a PAR bZIP transcription factor and identified the t(17;19)-generated E2A-HLF chimera as the molecular basis of a subset of B-lineage ALL, establishing the gene's dual identity in normal tissue-specific transcription and leukemogenesis.\",\n      \"evidence\": \"Molecular cloning, Northern blot, chimeric transcript sequencing, gel mobility shift assays showing homodimeric and heterodimeric DNA binding\",\n      \"pmids\": [\"1386162\", \"1516826\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Wild-type HLF function in hematopoiesis unknown\", \"Downstream targets of E2A-HLF unidentified\", \"Structural basis of dimerization preference unresolved\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Characterization of the HLF consensus binding site (5'-GTTACGTAAT-3'), identification of two isoforms from alternative promoters with distinct circadian amplitudes and target gene preferences, and mapping of the conserved THAD transactivation domain established the molecular toolkit for HLF-mediated transcription.\",\n      \"evidence\": \"In vitro binding site selection, reporter assays across cell types, alternative promoter mapping with CUG initiation, GAL4 fusion deletion analysis\",\n      \"pmids\": [\"8065331\", \"7556072\", \"8639829\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Crystal structure of HLF bZIP domain lacking\", \"Cofactors recruited by THAD unknown\", \"Chromatin-level target gene regulation not explored\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Demonstration that E2A-HLF blocks apoptosis (both IL-3 withdrawal and p53-mediated) rather than promoting proliferation resolved a fundamental question about the oncogenic mechanism, showing the chimera sustains cell survival.\",\n      \"evidence\": \"Dominant-negative E2A-HLF suppression in t(17;19) leukemia cells, IL-3 deprivation and p53-mediated apoptosis assays in pro-B cells\",\n      \"pmids\": [\"8700228\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream survival effectors of E2A-HLF not yet identified\", \"Mechanism by which survival is uncoupled from growth unclear\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Identification of SLUG as an E2A-HLF-activated antiapoptotic effector, demonstration that E2A-HLF transforms through homodimeric (gain-of-function) rather than dominant-negative binding, and in vivo transgenic modeling showing E2A-HLF disrupts lymphoid development requiring additional cooperating events, collectively defined the leukemogenic pathway.\",\n      \"evidence\": \"SLUG identification and IL-3 withdrawal rescue, leucine zipper mutagenesis separating homo- from heterodimer function, E2A-HLF transgenic mouse with lymphoid defects and T-ALL\",\n      \"pmids\": [\"10518215\", \"9032268\", \"10216071\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct promoter binding by E2A-HLF to SLUG not shown\", \"Full repertoire of cooperating mutations unknown\", \"Wild-type HLF role in normal B-cell development unaddressed\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Discovery that E2A-HLF activates Groucho-related corepressors and can function through protein-protein interactions independent of direct DNA binding expanded the mechanistic model beyond simple sequence-specific transactivation.\",\n      \"evidence\": \"RDA in zinc-inducible FL5.12 pro-B cell system, DNA-binding-disabled E2A-HLF mutant retaining survival activity\",\n      \"pmids\": [\"11486032\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of protein partners mediating DNA-binding-independent activity unknown\", \"Groucho targets downstream of E2A-HLF not defined\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Triple knockout of all three PAR bZIP factors (DBP/TEF/HLF) revealed their collective role in circadian xenobiotic detoxification, providing the first in vivo physiological function for HLF outside of hematopoiesis and cancer.\",\n      \"evidence\": \"PAR bZIP triple knockout mouse with liver/kidney transcriptome profiling and xenobiotic hypersensitivity\",\n      \"pmids\": [\"16814730\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Individual contribution of HLF vs. DBP vs. TEF to detoxification gene regulation unresolved\", \"Cardiovascular phenotype later found in triple KO not yet attributed to specific PAR factor\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identification of LMO2 and BCL-2 as direct E2A-HLF targets whose combined expression recapitulates E2A-HLF immortalization, and ZNF521 as a cooperating gene, defined the minimal oncogenic circuitry for E2A-HLF-driven B-ALL.\",\n      \"evidence\": \"ChIP/reporter for LMO2, shRNA and pharmacological BCL-2 inhibition, retroviral insertional mutagenesis identifying ZNF521 in E2A-HLF knock-in mice\",\n      \"pmids\": [\"20519628\", \"21072044\", \"20062079\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether LMO2/BCL-2 sufficiency applies in human primary leukemia cells untested\", \"Mechanism of ZNF521 cooperation with E2A-HLF unclear\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Placing HLF downstream of MEIS1 in MLL-fusion leukemia, where HLF rescues oxidative stress and leukemia maintenance in Meis1-deficient cells, established HLF as a functional effector of the MEIS1-dependent stem cell program beyond the t(17;19) context.\",\n      \"evidence\": \"Inducible Meis1 knockout crossed with MLL-AF9 knock-in, ChIP-confirmed MEIS1 binding to HLF locus, HLF rescue of leukemia in vivo\",\n      \"pmids\": [\"25740828\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets of wild-type HLF in leukemia maintenance undefined\", \"Whether HLF regulates ROS through xenobiotic enzymes or other pathways unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Discovery of the HLF/IL-6/STAT3 feedforward circuit in hepatic stellate cells, validated by HLF-knockout mice with attenuated fibrosis, established the first non-hematopoietic, non-circadian disease mechanism for wild-type HLF.\",\n      \"evidence\": \"HLF-knockout mouse model, primary HSC isolation, LX2 human HSC line, HLF gain/loss-of-function with IL-6/STAT3 pathway measurement\",\n      \"pmids\": [\"28754776\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct HLF binding sites on the IL-6 promoter not mapped by ChIP-seq\", \"Whether HLF has roles in other fibrotic organs beyond liver unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Genome-wide ChIP-seq of endogenous TCF3-HLF revealed it hijacks HLF binding sites at HSC/myeloid super-enhancers to activate MYC and cooperates with ERG and EP300, while parallel studies showed HLF marks the entire HSC developmental continuum from arterial endothelium through the Evi-1/HLF axis, unifying the fusion oncogene's mechanism with normal HSC biology.\",\n      \"evidence\": \"ChIP-seq, CRISPRi, EP300 inhibitor treatment, Hlf-tdTomato knock-in reporter mouse, in vivo transplantation, Evi-1/Hlf axis characterization\",\n      \"pmids\": [\"31735627\", \"31076455\", \"31118247\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether EP300 inhibitors have therapeutic efficacy in patients with t(17;19) ALL untested\", \"How HLF binding site specificity differs between HSCs and leukemia cells unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Genomic HLF reporter strategies and lineage tracing in human and mouse systems confirmed HLF as one of the most specific transcriptional markers defining HSC identity, with HLF+ cells comprising all long-term repopulating stem cell activity.\",\n      \"evidence\": \"HLF-tdTomato reporter, HLF-CreER lineage tracing at E9.5, serial transplantation, single-cell transcriptomics\",\n      \"pmids\": [\"34499717\", \"34589491\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequences of HLF loss specifically in adult HSCs (single-gene knockout) not reported\", \"Whether HLF is instructive or merely correlative for HSC identity unresolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"In solid tumors, HLF was shown to transactivate GGT1 to confer ferroptosis resistance in TNBC downstream of macrophage-derived TGF-β1 signaling, revealing a cancer-type-specific mechanism distinct from its leukemic or hepatic roles.\",\n      \"evidence\": \"ChIP/reporter for HLF→GGT1, ferroptosis assays, TNBC xenograft with cytokine pathway inhibition\",\n      \"pmids\": [\"34991659\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether HLF-mediated ferroptosis resistance is generalizable to other cancer types unknown\", \"Direct structural basis of HLF target gene selectivity across tissues unresolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"An in vivo CRISPR screen identified HLF as a metastasis suppressor in ccRCC, epigenetically silenced by BRG1, that restrains invasion through LPXN/Paxillin-mediated cytoskeletal regulation, establishing a tumor-suppressive role directly opposing its oncogenic functions in other contexts.\",\n      \"evidence\": \"Genome-wide in vivo CRISPR screen, HLF overexpression/depletion in metastasis assays, BRG1 ChIP, LPXN/Paxillin pathway characterization\",\n      \"pmids\": [\"40473600\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How the same transcription factor acts as oncogene vs. tumor suppressor in different tissues remains mechanistically unexplained\", \"Whether BRG1-mediated silencing of HLF occurs in cancers beyond ccRCC untested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identification of TFEB and IL-6R as direct HLF targets in gallbladder cancer stem cells, driving autophagy-dependent drug resistance and PD-L1-mediated immune evasion, extended HLF's target repertoire to immune-modulatory and autophagy pathways.\",\n      \"evidence\": \"CUT&Tag/ChIP for HLF→TFEB/IL-6R, xenograft/PDX models, CD8+ T cell depletion experiments\",\n      \"pmids\": [\"40779629\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether HLF-TFEB axis operates in non-cancer stem cells unknown\", \"Therapeutic targeting of HLF itself remains unexplored\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: how HLF exerts opposing oncogenic versus tumor-suppressive functions across tissue contexts, what the functional consequences of isolated HLF loss are in adult HSCs, and whether HLF can be directly targeted therapeutically.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No conditional single-gene HLF knockout in adult HSCs reported\", \"No crystal structure of HLF bZIP domain available\", \"Tissue-specific cofactor interactions determining target gene selectivity uncharacterized\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 1, 2, 6]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [3, 6, 17, 34, 35, 43, 45, 47, 50]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": []},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [3, 6, 17, 34, 35, 45, 50]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [34, 43, 45, 50]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [5, 10, 12, 24, 26, 27]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [38, 41, 42, 49]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 4, 13, 28, 36]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [50]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"DBP\",\n      \"TEF\",\n      \"E2A\",\n      \"MEIS1\",\n      \"ERG\",\n      \"EP300\",\n      \"STAT3\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}